Saccharomyces cerevisiae metabolite - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	Saccharomyces cerevisiae metabolite	go back to main search page
Accession:	CHEBI:75772	browse the term
Definition:	Any fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Synonyms:	related_synonym:	S. cerevisiae metabolite; S. cerevisiae metabolites; S. cerevisiae secondary metabolite; S. cerevisiae secondary metabolites; Saccharomyces cerevisiae metabolites; Saccharomyces cerevisiae secondary metabolites; baker's yeast metabolite; baker's yeast metabolites; baker's yeast secondary metabolite; baker's yeast secondary metabolites
	alt_id:	CHEBI:76949; CHEBI:76951

show annotations for term's descendants Sort by:
Rat (17501) Mouse (18261) Human (20188) Chinchilla (0) Bonobo (0) Dog (92) Squirrel (0) Pig (314) Green Monkey (1) Naked Mole-rat (0) All
Genes (314)

(R)-carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 5

increases uptake

SLC22A5 protein results in increased uptake of Carnitine

NCBI chr 2:134,660,741...134,847,575
Ensembl chr 2:134,660,808...134,686,219

2-deoxy-D-glucose

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

[Antimycin A co-treated with Deoxyglucose] results in increased expression of BAX protein; Quercetin inhibits the reaction [[Antimycin A co-treated with Deoxyglucose] results in increased expression of BAX protein]

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140

G

mechanistic target of rapamycin kinase

multiple interactions

[Antimycin A co-treated with Deoxyglucose] results in decreased phosphorylation of MTOR protein; Quercetin promotes the reaction [[Antimycin A co-treated with Deoxyglucose] results in decreased phosphorylation of MTOR protein]

NCBI chr 6:71,286,989...71,412,913
Ensembl chr 6:71,286,989...71,412,888

G

nitric oxide synthase 3

decreases expression

Deoxyglucose results in decreased expression of NOS3 mRNA

NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943

3',5'-cyclic GMP

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

phosphodiesterase 5A

increases degradation

PDE5 protein results in increased degradation of Cyclic GMP

NCBI chr 8:104,270,858...104,420,955
Ensembl chr 8:104,270,881...104,420,953

G

phosphodiesterase 6C

increases degradation

PDE6C protein results in increased degradation of Cyclic GMP

NCBI chr14:105,010,974...105,122,628
Ensembl chr14:105,050,691...105,122,421

G

protein kinase cGMP-dependent 1

increases activity

Cyclic GMP results in increased activity of PRKG1 protein

NCBI chr14:97,558,531...98,793,080
Ensembl chr14:97,558,533...98,793,010

3-methyladenine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

3-methyladenine inhibits the reaction [Zinc Sulfate results in increased expression of BAX mRNA]

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140

G

beclin 1

multiple interactions

3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of BECN1 mRNA]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of BECN1 protein]]; 3-methyladenine inhibits the reaction [Zinc Sulfate results in increased expression of BECN1 protein]

PMID:28803810 PMID:34811946

NCBI chr12:20,041,914...20,054,249
Ensembl chr12:20,041,956...20,054,373

G

caspase 3

multiple interactions

3-methyladenine inhibits the reaction [Zinc Sulfate results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]

PMID:28803810 PMID:30287338

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

caspase 8

multiple interactions

3-methyladenine inhibits the reaction [Zinc Sulfate results in increased cleavage of CASP8 protein]

NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468

G

catalase

multiple interactions

3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the activity of CAT protein]

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

cytochrome c, somatic

multiple interactions

3-methyladenine inhibits the reaction [Zinc Sulfate results in increased expression of CYCS mRNA]

NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866

G

dynactin subunit 4

multiple interactions

3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of DCTN4 mRNA]

NCBI chr 2:151,681,001...151,713,923
Ensembl chr 2:151,681,003...151,783,746

G

FYVE, RhoGEF and PH domain containing 4

multiple interactions

3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L mRNA]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L protein]]

NCBI chr 5:41,571,054...41,636,058
Ensembl chr 5:41,570,282...41,636,028

G

fission, mitochondrial 1

multiple interactions

3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of FIS1 mRNA]]

NCBI chr 3:8,938,250...8,942,102
Ensembl chr 3:8,937,453...8,946,955

G

glutathione peroxidase 1

multiple interactions

3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of GPX1 mRNA]

NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433

G

lysosomal associated membrane protein 2

decreases expression

3-methyladenine results in decreased expression of LAMP2 protein

NCBI chr X:98,586,718...98,623,939
Ensembl chr X:98,556,710...98,623,940

G

microtubule associated protein 1 light chain 3 beta

multiple interactions
decreases lipidation

3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the lipidation of MAP1LC3B protein]]; Benzo(a)pyrene promotes the reaction [3-methyladenine results in decreased lipidation of MAP1LC3B protein]

PMID:34811946 PMID:36754226

NCBI chr 6:1,919,879...1,941,069
Ensembl chr 6:1,915,387...1,941,069

G

marker of proliferation Ki-67

multiple interactions

3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of MKI67 protein]]

NCBI chr14:137,266,622...137,296,312

G

MYD88 innate immune signal transduction adaptor

multiple interactions

3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the activity of CAT protein]; 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of BECN1 mRNA]; 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of DCTN4 mRNA]; 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of GPX1 mRNA]; 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of SOD1 mRNA]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of MKI67 protein]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of OPA1 mRNA]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of TOMM20 protein]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L mRNA]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L protein]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of FIS1 mRNA]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of PARP1 protein]]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of BECN1 protein]]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of SQSTM1 protein]]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the lipidation of MAP1LC3B protein]]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the phosphorylation of TP53 protein]]

NCBI chr13:22,976,951...22,979,568
Ensembl chr13:22,966,137...22,983,109

G

OPA1 mitochondrial dynamin like GTPase

multiple interactions

3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of OPA1 mRNA]]

NCBI chr13:130,624,771...130,718,345
Ensembl chr13:130,624,796...130,719,083

G

poly(ADP-ribose) polymerase 1

multiple interactions

3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of PARP1 protein]]; 3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein]

PMID:30287338 PMID:34811946

NCBI chr10:14,203,157...14,241,164
Ensembl chr10:14,203,160...14,241,196

G

superoxide dismutase 1

multiple interactions

3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of SOD1 mRNA]

NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729

G

sequestosome 1

multiple interactions

3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of SQSTM1 protein]]; 3-methyladenine inhibits the reaction [Zinc Sulfate results in decreased expression of SQSTM1 protein]

PMID:28803810 PMID:34811946

NCBI chr 2:78,752,768...78,763,998
Ensembl chr 2:78,752,771...78,763,938

G

translocase of outer mitochondrial membrane 20

multiple interactions

3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of TOMM20 protein]]

NCBI chr14:56,113,087...56,127,686
Ensembl chr14:56,113,192...56,127,677

G

tumor protein p53

multiple interactions

3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the phosphorylation of TP53 protein]]

NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818

6-propyl-2-thiouracil

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

thyroid peroxidase

decreases activity

Propylthiouracil results in decreased activity of TPO protein

NCBI chr 3:132,384,677...132,409,750
Ensembl chr 3:132,384,583...132,409,208

adenosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

myosin light chain 9

decreases phosphorylation
multiple interactions

Adenosine results in decreased phosphorylation of MYL9 protein
8-phenyltheophylline inhibits the reaction [Adenosine results in decreased phosphorylation of MYL9 protein]

NCBI chr17:39,788,165...39,795,240
Ensembl chr17:39,788,199...39,795,293

ammonium chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

RUNX family transcription factor 2

multiple interactions

Ammonium Chloride inhibits the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 mRNA]]

NCBI chr 7:40,106,581...40,353,304
Ensembl chr 7:40,106,532...40,460,687

G

SRY-box transcription factor 5

multiple interactions

Ammonium Chloride inhibits the reaction [SOX5 protein inhibits the reaction [Warfarin results in increased expression of RUNX2 mRNA]]

NCBI chr 5:49,159,950...50,166,463
Ensembl chr 5:49,504,551...50,161,558

aspartame

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutamyl aminopeptidase

multiple interactions
increases hydrolysis

1,10-phenanthroline inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame]; amastatin inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame]; Calcium Chloride promotes the reaction [ENPEP protein results in increased hydrolysis of Aspartame]

NCBI chr 8:111,765,839...111,858,349
Ensembl chr 8:111,748,514...111,858,510

ATP

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 apoptosis regulator

increases expression
multiple interactions

Adenosine Triphosphate results in increased expression of BCL2 protein
tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased expression of BCL2 protein]

NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879

G

caspase 8

increases activity
multiple interactions

Adenosine Triphosphate results in increased activity of CASP8 protein
tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased activity of CASP8 protein]

NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468

G

cytochrome c, somatic

affects localization
multiple interactions

Adenosine Triphosphate affects the localization of CYCS protein
[Calcium co-treated with Phosphates co-treated with Adenosine Triphosphate] affects the localization of CYCS protein; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate affects the localization of CYCS protein]

PMID:16489745 PMID:17997382

NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866

G

myosin light chain 9

decreases phosphorylation
multiple interactions

Adenosine Triphosphate results in decreased phosphorylation of MYL9 protein
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein]]; Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein]

NCBI chr17:39,788,165...39,795,240
Ensembl chr17:39,788,199...39,795,293

G

tumor necrosis factor

increases expression
multiple interactions

Adenosine Triphosphate results in increased expression of TNF protein
tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased expression of TNF protein]

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416

benazepril

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

kininogen 1

increases activity

benazepril results in increased activity of KNG1 protein modified form

NCBI chr13:124,521,276...124,557,384
Ensembl chr13:124,521,340...124,557,958

bethanechol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-X-C motif chemokine ligand 10

increases expression

Bethanechol results in increased expression of CXCL10 mRNA

NCBI chr 8:71,693,641...71,695,948
Ensembl chr 8:71,693,339...71,695,948

G

C-X-C motif chemokine ligand 8

increases expression

Bethanechol results in increased expression of CXCL8 mRNA

NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861

G

interferon gamma

increases expression

Bethanechol results in increased expression of IFNG mRNA

NCBI chr 5:32,477,906...32,482,670
Ensembl chr 5:32,477,906...32,482,670

G

interleukin 17A

increases expression

Bethanechol results in increased expression of IL17A mRNA

NCBI chr 7:46,013,584...46,017,161
Ensembl chr 7:46,013,584...46,017,153

G

interleukin 1 alpha

increases expression

Bethanechol results in increased expression of IL1A mRNA

NCBI chr 3:43,718,320...43,731,668
Ensembl chr 3:43,718,368...43,731,119

Butyrylcholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

butyrylcholinesterase

increases hydrolysis

BCHE protein results in increased hydrolysis of butyrylcholine

NCBI chr13:104,946,732...105,007,568

butyrylthiocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

butyrylcholinesterase

increases hydrolysis

BCHE protein results in increased hydrolysis of Butyrylthiocholine

NCBI chr13:104,946,732...105,007,568

caffeine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATM serine/threonine kinase

multiple interactions

Caffeine inhibits the reaction [deoxynivalenol results in increased phosphorylation of ATM protein]

NCBI chr 9:36,620,656...36,759,555
Ensembl chr 9:36,620,658...36,759,552

G

cyclin B1

multiple interactions

Caffeine inhibits the reaction [deoxynivalenol results in decreased expression of CCNB1 protein]

NCBI chr16:47,338,239...47,348,385
Ensembl chr16:47,338,110...47,348,377

G

cell division cycle 25C

multiple interactions

Caffeine inhibits the reaction [deoxynivalenol results in decreased expression of CDC25C protein]

NCBI chr 2:140,289,156...140,323,696
Ensembl chr 2:140,289,115...140,324,425

G

cyclin dependent kinase 1

multiple interactions

Caffeine inhibits the reaction [deoxynivalenol results in decreased expression of CDK1 protein]

NCBI chr14:64,233,945...64,255,290
Ensembl chr14:64,233,987...64,372,197

G

checkpoint kinase 2

multiple interactions

Caffeine inhibits the reaction [deoxynivalenol results in increased phosphorylation of CHEK2 protein]

NCBI chr14:45,699,833...45,967,350
Ensembl chr14:45,929,715...45,967,290

G

ryanodine receptor 1

increases activity
multiple interactions

Caffeine results in increased activity of RYR1 protein; Caffeine results in increased activity of RYR1 protein mutant form
Caffeine promotes the reaction [Ryanodine binds to RYR1 protein mutant form]; Caffeine promotes the reaction [Ryanodine binds to RYR1 protein]; Dantrolene inhibits the reaction [Caffeine promotes the reaction [Ryanodine binds to RYR1 protein mutant form]]; Dantrolene inhibits the reaction [Caffeine promotes the reaction [Ryanodine binds to RYR1 protein]]; Dantrolene inhibits the reaction [Caffeine results in increased activity of RYR1 protein mutant form]; Dantrolene inhibits the reaction [Caffeine results in increased activity of RYR1 protein]

NCBI chr 6:47,339,759...47,458,457
Ensembl chr 6:47,343,768...47,458,458

CAR(3:0(Me2))

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 5

decreases activity

pivaloylcarnitine results in decreased activity of SLC22A5 protein

NCBI chr 2:134,660,741...134,847,575
Ensembl chr 2:134,660,808...134,686,219

carbon dioxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adenylate cyclase activating polypeptide 1

multiple interactions

[Carbon Dioxide co-treated with Oxygen deficiency] results in decreased expression of ADCYAP1 protein; Nicotine inhibits the reaction [[Carbon Dioxide co-treated with Oxygen deficiency] results in decreased expression of ADCYAP1 protein]

NCBI chr 6:105,414,628...105,422,294
Ensembl chr 6:105,414,631...105,422,294

G

ADCYAP receptor type I

multiple interactions

[Carbon Dioxide co-treated with Oxygen deficiency] results in decreased expression of ADCYAP1R1 protein

NCBI chr18:41,915,180...41,972,327
Ensembl chr18:41,917,428...41,972,301

G

cholinergic receptor nicotinic alpha 2 subunit

multiple interactions

[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNA2 protein; Nicotine affects the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNA2 protein]

NCBI chr14:11,193,732...11,204,334
Ensembl chr14:11,195,228...11,207,650

G

cholinergic receptor nicotinic alpha 3 subunit

multiple interactions

[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNA3 protein; Nicotine affects the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNA3 protein]

NCBI chr 7:47,361,710...47,382,743
Ensembl chr 7:47,361,899...47,384,303

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNA7 protein; Nicotine affects the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNA7 protein]

NCBI chr 1:142,803,697...142,937,124
Ensembl chr 1:142,803,701...142,937,123

G

cholinergic receptor nicotinic alpha 9 subunit

multiple interactions

[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNA9 protein; Nicotine affects the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNA9 protein]

NCBI chr 8:31,430,933...31,456,385
Ensembl chr 8:31,443,043...31,456,384

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNB2 protein; Nicotine affects the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNB2 protein]

NCBI chr 4:95,196,992...95,211,084
Ensembl chr 4:95,198,717...95,211,037

chlorotoluron

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450 family 2 subfamily B member 6B

decreases response to substance

CYP2B6B protein results in decreased susceptibility to chlortoluron

NCBI chr 6:49,158,175...49,173,872
Ensembl chr 6:49,110,812...49,178,334

G

cytochrome P450 2C49

decreases response to substance

CYP2C49 protein results in decreased susceptibility to chlortoluron

NCBI chr14:106,571,803...106,612,082
Ensembl chr14:106,285,173...106,612,455

choline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catalase

multiple interactions

[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] promotes the reaction [bisphenol A results in decreased expression of CAT protein]; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT mRNA; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT protein

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

DNA methyltransferase 1

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT1 mRNA

NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844

G

DNA methyltransferase 3 alpha

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of DNMT3A mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT3A mRNA

NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,603,087

G

glutathione peroxidase 1

multiple interactions

[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of GPX1 mRNA; [bisphenol A co-treated with [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12]] results in increased expression of GPX1 mRNA

NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433

G

glycogen synthase 1

multiple interactions

[Betaine co-treated with Choline co-treated with Folic Acid co-treated with bisphenol A] results in increased methylation of GYS1 promoter; [Betaine co-treated with Choline co-treated with Folic Acid] results in decreased expression of GYS1 mRNA; [Betaine co-treated with Choline co-treated with Folic Acid] results in increased methylation of GYS1 promoter

NCBI chr 6:54,234,600...54,250,211
Ensembl chr 6:54,233,050...54,250,261

G

lactate dehydrogenase A

multiple interactions

[bisphenol A co-treated with Choline co-treated with Folic Acid co-treated with Betaine] results in decreased methylation of LDHA promoter

NCBI chr 2:40,814,163...40,827,284
Ensembl chr 2:40,814,169...40,826,715

G

methylenetetrahydrofolate reductase

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of MTHFR mRNA

NCBI chr 6:71,863,637...71,882,118
Ensembl chr 6:71,863,637...71,881,820

G

sucrase-isomaltase

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SI mRNA

NCBI chr13:104,296,281...104,379,558
Ensembl chr13:104,296,283...104,379,478

G

solute carrier family 15 member 1

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of SLC15A1 mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased methylation of SLC15A1 promoter]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC15A1 mRNA

NCBI chr11:67,652,808...67,690,457
Ensembl chr11:67,652,193...67,710,933

G

solute carrier family 5 member 1

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with bisphenol A] results in increased expression of SLC5A1 mRNA; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC5A1 mRNA

NCBI chr14:48,566,400...48,704,145
Ensembl chr14:48,628,224...48,705,841

G

superoxide dismutase 1

multiple interactions

[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of SOD1 mRNA

NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729

clofibrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aconitase 1

increases expression

Clofibrate results in increased expression of ACO1 mRNA

NCBI chr10:33,937,833...34,001,895
Ensembl chr10:33,937,833...34,001,900

G

acyl-CoA oxidase 1

increases expression

Clofibrate results in increased expression of ACOX1 mRNA

PMID:16896063 PMID:17437637

NCBI chr12:5,450,913...5,479,550
Ensembl chr12:5,439,361...5,479,546

G

angiotensinogen

multiple interactions

Clofibrate inhibits the reaction [AGT protein modified form results in increased expression of EDN1 protein]

NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,656,833

G

albumin

decreases expression

Clofibrate results in decreased expression of ALB mRNA

NCBI chr 8:69,643,427...69,663,152
Ensembl chr 8:69,531,487...69,721,696

G

BCL2 associated X, apoptosis regulator

increases expression

Clofibrate results in increased expression of BAX mRNA

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140

G

BCL2 like 1

decreases expression

Clofibrate results in decreased expression of BCL2L1 mRNA

NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,143...35,414,694

G

catalase

increases expression

Clofibrate results in increased expression of CAT mRNA

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

carnitine palmitoyltransferase 1A

increases expression

Clofibrate results in increased expression of CPT1A mRNA

PMID:16896063 PMID:17363680

NCBI chr 2:4,250,642...4,293,914
Ensembl chr 2:4,233,099...4,293,911

G

cathepsin B

increases expression

Clofibrate results in increased expression of CTSB mRNA

NCBI chr14:15,014,139...15,035,081
Ensembl chr14:15,011,711...15,033,877

G

iodothyronine deiodinase 2

decreases expression

Clofibrate results in decreased expression of DIO2 mRNA

NCBI chr 7:103,096,414...103,110,749
Ensembl chr 7:103,096,433...103,323,258

G

endothelin 1

decreases expression
multiple interactions

Clofibrate results in decreased expression of EDN1 protein
Clofibrate inhibits the reaction [AGT protein modified form results in increased expression of EDN1 protein]; Clofibrate inhibits the reaction [KNG1 protein modified form results in increased expression of EDN1 protein]; Clofibrate inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EDN1 protein]; Nitric Oxide deficiency inhibits the reaction [Clofibrate results in decreased expression of EDN1 protein]

NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348

G

fatty acid binding protein 1

increases expression

Clofibrate results in increased expression of FABP1 mRNA

NCBI chr 3:57,850,511...57,854,966
Ensembl chr 3:57,850,499...57,854,956

G

glutathione peroxidase 1

decreases expression

Clofibrate results in decreased expression of GPX1 mRNA

NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

increases expression

Clofibrate results in increased expression of HMGCS2 mRNA

NCBI chr 4:101,420,941...101,440,302
Ensembl chr 4:101,420,872...101,438,126

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

Clofibrate results in increased expression of JUN mRNA

NCBI chr 6:153,686,425...153,687,635
Ensembl chr 6:153,685,682...153,687,636

G

kininogen 1

multiple interactions

Clofibrate inhibits the reaction [KNG1 protein modified form results in increased expression of EDN1 protein]

NCBI chr13:124,521,276...124,557,384
Ensembl chr13:124,521,340...124,557,958

G

MYC proto-oncogene, bHLH transcription factor

increases expression

Clofibrate results in increased expression of MYC mRNA

NCBI chr 4:12,455,141...12,460,360
Ensembl chr 4:12,455,122...12,461,078

G

nitric oxide synthase 3

increases expression
multiple interactions

Clofibrate results in increased expression of NOS3 protein
calphostin C inhibits the reaction [Clofibrate results in increased expression of NOS3 protein]

NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943

G

peroxisome proliferator activated receptor alpha

increases expression
multiple interactions

Clofibrate results in increased expression of PPARA; Clofibrate results in increased expression of PPARA protein
calphostin C inhibits the reaction [Clofibrate results in increased expression of PPARA protein]; calphostin C inhibits the reaction [Clofibrate results in increased expression of PPARA]; Tetradecanoylphorbol Acetate inhibits the reaction [Clofibrate results in increased expression of PPARA]

PMID:17105827 PMID:20568414

NCBI chr 5:3,302,755...3,321,091
Ensembl chr 5:3,300,741...3,364,239

G

stearoyl-CoA desaturase

increases expression

Clofibrate results in increased expression of SCD mRNA

NCBI chr14:111,461,560...111,478,033
Ensembl chr14:111,461,569...111,478,020

G

solute carrier family 5 member 5

increases expression

Clofibrate results in increased expression of SLC5A5 mRNA

NCBI chr 2:59,869,157...59,885,086
Ensembl chr 2:59,869,155...59,885,266

G

superoxide dismutase 1

increases expression

Clofibrate results in increased expression of SOD1 mRNA

NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729

G

thyroid hormone receptor alpha

decreases expression

Clofibrate results in decreased expression of THRA mRNA

NCBI chr12:22,270,506...22,296,684
Ensembl chr12:22,270,062...22,296,618

G

tumor necrosis factor

decreases expression

Clofibrate results in decreased expression of TNF mRNA

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416

G

thyroid peroxidase

increases expression

Clofibrate results in increased expression of TPO mRNA

NCBI chr 3:132,384,677...132,409,750
Ensembl chr 3:132,384,583...132,409,208

G

thyroid stimulating hormone receptor

increases expression

Clofibrate results in increased expression of TSHR mRNA

NCBI chr 7:103,768,260...103,925,777
Ensembl chr 7:103,768,296...103,925,922

G

transthyretin

decreases expression

Clofibrate results in decreased expression of TTR mRNA

NCBI chr 6:115,496,338...115,503,974
Ensembl chr 6:115,496,326...115,503,977

diethyl maleate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

peroxiredoxin 2

decreases activity

diethyl maleate results in decreased activity of PRDX2 protein

NCBI chr 2:66,207,829...66,211,474
Ensembl chr 2:66,207,828...66,212,009

dioxygen

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adenylate cyclase activating polypeptide 1

multiple interactions

[Carbon Dioxide co-treated with Oxygen deficiency] results in decreased expression of ADCYAP1 protein; Nicotine inhibits the reaction [[Carbon Dioxide co-treated with Oxygen deficiency] results in decreased expression of ADCYAP1 protein]

NCBI chr 6:105,414,628...105,422,294
Ensembl chr 6:105,414,631...105,422,294

G

ADCYAP receptor type I

multiple interactions

[Carbon Dioxide co-treated with Oxygen deficiency] results in decreased expression of ADCYAP1R1 protein

NCBI chr18:41,915,180...41,972,327
Ensembl chr18:41,917,428...41,972,301

G

calpain 1

multiple interactions
increases expression
increases activity

Dactinomycin inhibits the reaction [Oxygen deficiency results in increased expression of CAPN1 mRNA]
Oxygen deficiency results in increased activity of CAPN1 protein

NCBI chr 2:6,997,513...7,024,410
Ensembl chr 2:6,997,985...7,022,684

G

cholinergic receptor nicotinic alpha 2 subunit

multiple interactions

[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNA2 protein; Nicotine affects the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNA2 protein]

NCBI chr14:11,193,732...11,204,334
Ensembl chr14:11,195,228...11,207,650

G

cholinergic receptor nicotinic alpha 3 subunit

multiple interactions

[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNA3 protein; Nicotine affects the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNA3 protein]

NCBI chr 7:47,361,710...47,382,743
Ensembl chr 7:47,361,899...47,384,303

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNA7 protein; Nicotine affects the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNA7 protein]

NCBI chr 1:142,803,697...142,937,124
Ensembl chr 1:142,803,701...142,937,123

G

cholinergic receptor nicotinic alpha 9 subunit

multiple interactions

[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNA9 protein; Nicotine affects the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNA9 protein]

NCBI chr 8:31,430,933...31,456,385
Ensembl chr 8:31,443,043...31,456,384

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNB2 protein; Nicotine affects the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] affects the expression of CHRNB2 protein]

NCBI chr 4:95,196,992...95,211,084
Ensembl chr 4:95,198,717...95,211,037

G

nuclear factor kappa B subunit 1

affects localization

Oxygen deficiency affects the localization of NFKB1 protein

NCBI chr 8:118,391,010...118,478,927
Ensembl chr 8:118,390,638...118,506,691

G

NFKB inhibitor alpha

increases expression
increases degradation

Oxygen deficiency results in increased expression of NFKBIA mRNA
Oxygen deficiency results in increased degradation of NFKBIA protein

NCBI chr 7:64,508,119...64,510,754
Ensembl chr 7:64,507,822...64,511,277

G

platelet and endothelial cell adhesion molecule 1

multiple interactions

[[sodium percarbonate co-treated with calcium peroxide] results in increased abundance of Oxygen] which results in increased expression of PECAM1 protein

NCBI chr12:14,667,643...14,723,296
Ensembl chr12:14,649,044...14,723,293

G

von Willebrand factor

multiple interactions

[[sodium percarbonate co-treated with calcium peroxide] results in increased abundance of Oxygen] which results in increased expression of VWF protein

NCBI chr 5:64,516,627...64,655,938
Ensembl chr 5:64,519,186...65,002,452

diprotium oxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aquaporin 1 (Colton blood group)

increases transport
multiple interactions

AQP1 protein results in increased transport of Water
Mercuric Chloride inhibits the reaction [AQP1 protein results in increased transport of Water]

NCBI chr18:42,063,482...42,076,741
Ensembl chr18:42,063,485...42,076,746

disodium selenite

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

activating transcription factor 4

multiple interactions

Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of ATF4 protein]

NCBI chr 5:8,742,964...8,745,752
Ensembl chr 5:8,742,967...8,745,368

G

activating transcription factor 6

multiple interactions

Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of ATF6 protein]

NCBI chr 4:88,591,279...88,806,156
Ensembl chr 4:88,591,288...88,805,304

G

BCL2 antagonist/killer 1

multiple interactions

Sodium Selenite inhibits the reaction [[Cadmium Chloride co-treated with MIR125A mRNA mutant form] results in increased expression of BAK1 protein]; Sodium Selenite inhibits the reaction [Cadmium Chloride results in increased expression of BAK1 protein]; Sodium Selenite inhibits the reaction [MIR125A mRNA mutant form results in increased expression of BAK1 protein]

NCBI chr 7:29,808,849...29,815,345

G

BCL2 associated X, apoptosis regulator

multiple interactions
affects expression

Sodium Selenite inhibits the reaction [[Cadmium Chloride co-treated with MIR125A mRNA mutant form] results in increased expression of BAX protein]; Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of BAX mRNA]; Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of BAX protein]; Sodium Selenite inhibits the reaction [Cadmium Chloride results in increased expression of BAX protein]; Sodium Selenite inhibits the reaction [MIR125A mRNA mutant form results in increased expression of BAX protein]
Sodium Selenite affects the expression of BAX mRNA

PMID:17342738 PMID:26607349 PMID:37108405

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140

G

BCL2 apoptosis regulator

multiple interactions

Sodium Selenite inhibits the reaction [bisphenol A results in decreased expression of BCL2 mRNA]; Sodium Selenite inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]; Sodium Selenite inhibits the reaction [Cadmium Chloride promotes the reaction [MIR125A mRNA mutant form results in decreased expression of BCL2 protein]]; Sodium Selenite inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein]; Sodium Selenite inhibits the reaction [MIR125A mRNA mutant form results in decreased expression of BCL2 protein]

PMID:26607349 PMID:37108405

NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879

G

BCL2 like 1

affects expression
multiple interactions

Sodium Selenite affects the expression of BCL2L1 mRNA
Sodium Selenite affects the reaction [bisphenol A results in decreased expression of BCL2L1 protein]

PMID:17342738 PMID:37108405

NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,143...35,414,694

G

caspase 3

multiple interactions
decreases expression

Sodium Selenite inhibits the reaction [[Cadmium Chloride co-treated with MIR125A mRNA mutant form] results in increased expression of CASP3 protein]; Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of CASP3 protein]; Sodium Selenite inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein]; Sodium Selenite inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]; Sodium Selenite inhibits the reaction [MIR125A mRNA mutant form results in increased expression of CASP3 protein]
Sodium Selenite results in decreased expression of CASP3 protein

PMID:15191356 PMID:17342738 PMID:26607349 PMID:37108405

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

caspase 8

multiple interactions

Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of CASP8 mRNA]

NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468

G

caspase 9

multiple interactions

Sodium Selenite inhibits the reaction [[Cadmium Chloride co-treated with MIR125A mRNA mutant form] results in increased expression of CASP9 protein]; Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of CASP9 mRNA]; Sodium Selenite inhibits the reaction [Cadmium Chloride results in increased expression of CASP9 protein]; Sodium Selenite inhibits the reaction [MIR125A mRNA mutant form results in increased expression of CASP9 protein]

PMID:26607349 PMID:37108405

NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007

G

catalase

multiple interactions

Sodium Selenite inhibits the reaction [bisphenol A results in decreased activity of CAT protein]

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

claudin 1

multiple interactions

Sodium Selenite inhibits the reaction [bisphenol A results in decreased expression of CLDN1 protein]

NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657

G

DNA damage inducible transcript 3

multiple interactions

Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of DDIT3 protein]

NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

Sodium Selenite inhibits the reaction [bisphenol A results in increased phosphorylation of EIF2AK3 protein]

NCBI chr 3:57,423,894...57,506,247
Ensembl chr 3:57,423,943...57,506,245

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of ERN1 protein]

NCBI chr12:14,881,913...14,963,290
Ensembl chr12:14,881,923...14,963,284

G

glutathione peroxidase 4

increases activity

Sodium Selenite results in increased activity of GPX4 protein

NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,931

G

heat shock protein family A (Hsp70) member 5

multiple interactions

Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of HSPA5 protein]

NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894

G

interferon gamma

multiple interactions

Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of IFNG mRNA]

NCBI chr 5:32,477,906...32,482,670
Ensembl chr 5:32,477,906...32,482,670

G

interleukin 10

multiple interactions

Sodium Selenite inhibits the reaction [bisphenol A results in decreased expression of IL10 mRNA]

NCBI chr 9:67,400,727...67,405,941
Ensembl chr 9:67,400,728...67,405,378

G

interleukin 17A

multiple interactions

Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of IL17A mRNA]

NCBI chr 7:46,013,584...46,017,161
Ensembl chr 7:46,013,584...46,017,153

G

interleukin 6

multiple interactions

Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]

NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263

G

interleukin-1 beta-like

multiple interactions

Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA]

G

mitogen-activated protein kinase 1

increases expression

Sodium Selenite results in increased expression of MAPK1 protein

NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513

G

mitogen-activated protein kinase 3

increases expression

Sodium Selenite results in increased expression of MAPK3 protein

NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567

G

microRNA mir-125a

multiple interactions

Sodium Selenite inhibits the reaction [[Cadmium Chloride co-treated with MIR125A mRNA mutant form] results in increased expression of BAK1 protein]; Sodium Selenite inhibits the reaction [[Cadmium Chloride co-treated with MIR125A mRNA mutant form] results in increased expression of BAX protein]; Sodium Selenite inhibits the reaction [[Cadmium Chloride co-treated with MIR125A mRNA mutant form] results in increased expression of CASP3 protein]; Sodium Selenite inhibits the reaction [[Cadmium Chloride co-treated with MIR125A mRNA mutant form] results in increased expression of CASP9 protein]; Sodium Selenite inhibits the reaction [Cadmium Chloride promotes the reaction [MIR125A mRNA mutant form results in decreased expression of BCL2 protein]]; Sodium Selenite inhibits the reaction [Cadmium results in decreased expression of MIR125A mRNA]; Sodium Selenite inhibits the reaction [MIR125A mRNA mutant form results in decreased expression of BCL2 protein]; Sodium Selenite inhibits the reaction [MIR125A mRNA mutant form results in increased expression of BAK1 protein]; Sodium Selenite inhibits the reaction [MIR125A mRNA mutant form results in increased expression of BAX protein]; Sodium Selenite inhibits the reaction [MIR125A mRNA mutant form results in increased expression of CASP3 protein]; Sodium Selenite inhibits the reaction [MIR125A mRNA mutant form results in increased expression of CASP9 protein]

NCBI chr 6:58,331,566...58,331,645
Ensembl chr 6:58,331,566...58,331,645

G

occludin

multiple interactions

Sodium Selenite affects the reaction [bisphenol A results in decreased expression of OCLN protein]

NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033

G

proopiomelanocortin

multiple interactions

Ditiocarb promotes the reaction [Sodium Selenite inhibits the reaction [POMC protein results in increased secretion of Hydrocortisone]]; Sodium Selenite inhibits the reaction [POMC protein results in increased secretion of Hydrocortisone]

NCBI chr 3:113,661,712...113,668,558
Ensembl chr 3:113,661,004...113,670,418

G

tight junction protein 1

multiple interactions

Sodium Selenite affects the reaction [bisphenol A results in decreased expression of TJP1 protein]

NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836

G

tumor necrosis factor

multiple interactions

Sodium Selenite inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416

enalaprilat dihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensinogen

decreases activity

Enalaprilat results in decreased activity of AGT protein modified form

NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,656,833

G

kininogen 1

increases activity

Enalaprilat results in increased activity of KNG1 protein modified form

NCBI chr13:124,521,276...124,557,384
Ensembl chr13:124,521,340...124,557,958

ethanol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA dehydrogenase long chain

increases expression

Ethanol results in increased expression of ACADL mRNA

NCBI chr15:112,935,631...112,969,381
Ensembl chr15:112,933,506...112,969,577

G

ADAM metallopeptidase with thrombospondin type 1 motif 8

increases expression

Ethanol results in increased expression of ADAMTS8 mRNA

NCBI chr 9:57,090,313...57,113,077
Ensembl chr 9:57,090,617...57,110,414

G

1-acylglycerol-3-phosphate O-acyltransferase 1

decreases expression

Ethanol results in decreased expression of AGPAT1 mRNA

NCBI chr 7:24,205,930...24,208,430
Ensembl chr 7:24,204,905...24,213,193

G

alkylglycerone phosphate synthase

decreases expression

Ethanol results in decreased expression of AGPS mRNA

NCBI chr15:83,146,063...83,285,905
Ensembl chr15:83,146,002...83,391,984

G

aldehyde dehydrogenase 9 family member A1

increases expression

Ethanol results in increased expression of ALDH9A1 mRNA

NCBI chr 4:85,029,914...85,057,650

G

arachidonate 5-lipoxygenase

increases expression

Ethanol results in increased expression of ALOX5 mRNA

NCBI chr14:90,859,209...90,907,084
Ensembl chr14:90,859,016...90,907,094

G

annexin A8

increases expression

Ethanol results in increased expression of ANXA8 mRNA

NCBI chr14:88,319,209...88,340,716

G

amyloid beta precursor protein

increases expression

Ethanol results in increased expression of APP mRNA

NCBI chr13:189,434,854...189,716,120
Ensembl chr13:189,435,094...189,716,056

G

arylsulfatase family member K

increases expression

Ethanol results in increased expression of ARSK mRNA

NCBI chr 2:102,164,089...102,210,293
Ensembl chr 2:102,164,222...102,212,780

G

ATPase H+ transporting V0 subunit d2

increases expression

Ethanol results in increased expression of ATP6V0D2 mRNA

NCBI chr 4:50,694,188...50,749,373
Ensembl chr 4:50,694,189...50,749,378

G

chromosome 5 C12orf57 homolog

increases expression

Ethanol results in increased expression of C12ORF57 mRNA

NCBI chr 5:63,779,510...63,781,307
Ensembl chr 5:63,779,513...63,781,517

G

cystathionine beta-synthase

multiple interactions

[Ethanol co-treated with Folic Acid deficiency] results in increased activity of CBS protein

NCBI chr13:206,205,942...206,231,363
Ensembl chr13:206,205,946...206,230,248

G

cyclin B1 interacting protein 1

decreases expression

Ethanol results in decreased expression of CCNB1IP1 mRNA

NCBI chr 7:78,553,680...78,576,057
Ensembl chr 7:78,564,122...78,575,462

G

CD109 molecule

increases expression

Ethanol results in increased expression of CD109 mRNA

NCBI chr 1:92,081,675...92,241,079
Ensembl chr 1:92,054,821...92,286,730

G

CD47 molecule

increases expression

Ethanol results in increased expression of CD47 mRNA

NCBI chr13:151,427,933...151,488,064
Ensembl chr13:151,429,288...151,488,544

G

claudin 4

decreases expression

Ethanol results in decreased expression of CLDN4 mRNA

NCBI chr 3:11,039,711...11,053,930
Ensembl chr 3:11,039,706...11,053,925

G

clusterin

increases expression

Ethanol results in increased expression of CLU mRNA

NCBI chr14:11,336,585...11,352,569
Ensembl chr14:11,336,595...11,349,764

G

cystathionine gamma-lyase

increases activity
multiple interactions

Ethanol results in increased activity of CTH protein
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of CTH protein

NCBI chr 6:142,454,922...142,486,352
Ensembl chr 6:142,454,914...142,486,367

G

cytochrome P450 family 51 subfamily A member 1

increases expression

Ethanol results in increased expression of CYP51 mRNA

NCBI chr 9:72,057,506...72,079,587
Ensembl chr 9:72,057,511...72,079,444

G

eukaryotic translation elongation factor 2

decreases expression

Ethanol results in decreased expression of EEF2 mRNA

NCBI chr 2:74,746,541...74,756,687
Ensembl chr 2:74,747,080...74,756,680

G

eukaryotic translation initiation factor 3 subunit L

decreases expression

Ethanol results in decreased expression of EIF3L mRNA

NCBI chr 5:9,970,013...9,996,086
Ensembl chr 5:9,968,428...10,000,092

G

fibulin 2

increases expression

Ethanol results in increased expression of FBLN2 mRNA

NCBI chr13:70,757,255...70,830,430
Ensembl chr13:70,757,265...70,830,388

G

FKBP prolyl isomerase 1A

decreases expression

Ethanol results in decreased expression of FKBP1A mRNA

NCBI chr17:33,910,047...33,935,212

G

alpha-L-fucosidase 1

increases expression

Ethanol results in increased expression of FUCA1 mRNA

NCBI chr 6:81,638,213...81,655,993
Ensembl chr 6:81,637,994...81,656,068

G

gamma-aminobutyric acid type A receptor subunit beta3

increases expression

Ethanol results in increased expression of GABRB3 mRNA

NCBI chr 1:140,566,443...140,906,516
Ensembl chr 1:140,566,540...140,905,623

G

glutamate-cysteine ligase catalytic subunit

increases expression
increases activity
multiple interactions

Ethanol results in increased expression of GCLC mRNA
Ethanol results in increased activity of GCLC protein
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of GCLC protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GCLC mRNA

NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,565...27,253,530

G

glutathione peroxidase 6

increases expression

Ethanol results in increased expression of GPX6 mRNA

NCBI chr 7:22,256,013...22,267,992
Ensembl chr 7:22,256,038...22,267,992

G

growth hormone regulated TBC protein 1

decreases expression

Ethanol results in decreased expression of GRTP1 mRNA

NCBI chr11:78,618,720...78,637,502
Ensembl chr11:78,618,713...78,637,478

G

glutathione-disulfide reductase

increases activity
increases expression
multiple interactions

Ethanol results in increased activity of GSR protein
Ethanol results in increased expression of GSR mRNA
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of GSR protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSR mRNA

NCBI chr15:54,382,564...54,433,989
Ensembl chr15:54,382,567...54,433,984

G

glutathione synthetase

increases expression
increases activity
multiple interactions

Ethanol results in increased expression of GSS mRNA
Ethanol results in increased activity of GSS protein
[Ethanol co-treated with Folic Acid deficiency] results in increased activity of GSS protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSS mRNA

NCBI chr17:38,316,199...38,342,253
Ensembl chr17:38,312,720...38,342,298

G

hydroxysteroid 17-beta dehydrogenase 1

increases expression

Ethanol results in increased expression of HSD17B1 mRNA

NCBI chr12:20,269,468...20,271,349
Ensembl chr12:20,269,056...20,271,548

G

hydroxysteroid 17-beta dehydrogenase 14

decreases expression

Ethanol results in decreased expression of HSD17B14 mRNA

NCBI chr 6:54,125,229...54,144,143

G

HtrA serine peptidase 1

increases expression

Ethanol results in increased expression of HTRA1 mRNA

NCBI chr14:132,043,044...132,103,590
Ensembl chr14:132,041,934...132,103,595

G

inter-alpha-trypsin inhibitor heavy chain 5

increases expression

Ethanol results in increased expression of ITIH5 mRNA

NCBI chr10:63,688,416...63,764,566
Ensembl chr10:63,688,427...63,767,118

G

KIAA1217

increases expression

Ethanol results in increased expression of KIAA1217 mRNA

NCBI chr10:50,706,713...51,032,010
Ensembl chr10:50,707,054...51,205,619

G

keratin 6A

increases expression

Ethanol results in increased expression of KRT6A mRNA

NCBI chr 5:17,830,147...17,851,113
Ensembl chr 5:17,780,928...17,868,402

G

mitochondrial import inner membrane translocase subunit TIM16

decreases expression

Ethanol results in decreased expression of PAM16 mRNA

NCBI chr 3:37,928,098...38,005,619
Ensembl chr 3:37,928,096...37,985,151

G

glutathione S-transferase alpha M14

increases expression
multiple interactions

Ethanol results in increased expression of GSTA1 mRNA
[Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSTA1 mRNA

NCBI chr 7:46,553,813...46,567,596

G

microtubule associated protein 1S

decreases expression

Ethanol results in decreased expression of MAP1S mRNA

NCBI chr 2:60,003,116...60,043,133
Ensembl chr 2:59,999,168...60,029,865

G

myo-inositol oxygenase

decreases expression

Ethanol results in decreased expression of MIOX mRNA

NCBI chr 5:249,312...251,547
Ensembl chr 5:248,235...251,553

G

MAPK interacting serine/threonine kinase 2

decreases expression

Ethanol results in decreased expression of MKNK2 mRNA

NCBI chr 2:76,510,302...76,522,885
Ensembl chr 2:76,510,303...76,522,883

G

N-acetylated alpha-linked acidic dipeptidase 2

increases expression

Ethanol results in increased expression of NAALAD2 mRNA

NCBI chr 9:23,106,795...23,161,825
Ensembl chr 9:23,111,059...23,161,832

G

pleckstrin homology domain containing O1

increases expression

Ethanol results in increased expression of PLEKHO1 mRNA

NCBI chr 4:98,924,115...98,934,610
Ensembl chr 4:98,923,996...98,934,189

G

protein kinase D3

increases expression

Ethanol results in increased expression of PRKD3 mRNA

NCBI chr 3:102,840,666...102,949,128
Ensembl chr 3:102,842,229...102,941,329

G

prion protein

increases expression

Ethanol results in increased expression of PRNP mRNA

NCBI chr17:13,694,195...13,705,126
Ensembl chr17:13,694,190...13,705,124

G

ribosomal protein L13a

decreases expression

Ethanol results in decreased expression of RPL13A mRNA

NCBI chr 6:54,551,772...54,568,752
Ensembl chr 6:54,551,533...54,561,489

G

scaffold attachment factor B

increases expression

Ethanol results in increased expression of SAFB mRNA

NCBI chr 2:73,300,624...73,334,494
Ensembl chr 2:73,300,632...73,334,494

G

solute carrier family 7 member 4

decreases expression

Ethanol results in decreased expression of SLC7A4 mRNA

NCBI chr14:50,631,693...50,638,381
Ensembl chr14:50,633,878...50,637,404

G

superoxide dismutase 1

multiple interactions
decreases activity

[Ethanol co-treated with Folic Acid deficiency] results in decreased activity of SOD1 protein
Ethanol results in decreased activity of SOD1 protein

NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729

G

superoxide dismutase 2

multiple interactions
increases activity

[Ethanol co-treated with Folic Acid deficiency] results in increased activity of SOD2 protein
Ethanol results in increased activity of SOD2 protein

NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560

G

serglycin

increases expression

Ethanol results in increased expression of SRGN mRNA

NCBI chr14:72,183,368...72,199,262
Ensembl chr14:72,183,363...72,199,250

G

syntaxin binding protein 2

decreases expression

Ethanol results in decreased expression of STXBP2 mRNA

NCBI chr 2:71,504,575...71,513,446
Ensembl chr 2:71,504,569...71,513,422

G

TIMP metallopeptidase inhibitor 2

increases expression

Ethanol results in increased expression of TIMP2 mRNA

NCBI chr12:3,254,794...3,300,835
Ensembl chr12:3,254,493...3,300,834

G

transmembrane protein 98

increases expression

Ethanol results in increased expression of TMEM98 mRNA

NCBI chr12:42,087,691...42,101,152
Ensembl chr12:42,083,553...42,100,494

G

troponin I3, cardiac type

decreases expression

Ethanol results in decreased expression of TNNI3 mRNA

NCBI chr 6:59,366,828...59,377,490
Ensembl chr 6:59,371,080...59,377,734
Ensembl chr 6:59,371,080...59,377,734

G

trafficking protein particle complex subunit 5

decreases expression

Ethanol results in decreased expression of TRAPPC5 mRNA

NCBI chr 2:71,470,441...71,472,614
Ensembl chr 2:71,470,445...71,472,549

G

tRNA phosphotransferase 1

decreases expression

Ethanol results in decreased expression of TRPT1 mRNA

NCBI chr 2:7,876,028...7,887,589
Ensembl chr 2:7,883,945...7,888,133

G

WAP four-disulfide core domain 1

increases expression

Ethanol results in increased expression of WFDC1 mRNA

NCBI chr 6:4,333,729...4,365,122
Ensembl chr 6:4,333,731...4,399,237

G

Wnt family member 5B

increases expression

Ethanol results in increased expression of WNT5B mRNA

NCBI chr 5:68,627,158...68,731,938
Ensembl chr 5:68,627,185...68,732,265

flunixin meglumine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family B (MDR/TAP), member 1

affects expression

flunixin meglumine affects the expression of ABCB1 mRNA

NCBI chr 9:93,049,955...93,146,469

G

cytochrome P450 family 1 subfamily A member 2

affects expression

flunixin meglumine affects the expression of CYP1A2 mRNA

NCBI chr 7:58,779,529...58,786,155
Ensembl chr 7:58,779,475...58,786,100

G

cytochrome P450 family 2 subfamily E member 1

affects expression

flunixin meglumine affects the expression of CYP2E1 mRNA

NCBI chr14:141,690,737...141,703,078
Ensembl chr14:141,690,426...141,736,817

G

cytochrome P450 family 3 subfamily A member 22

affects expression

flunixin meglumine affects the expression of CYP3A22 mRNA

NCBI chr 3:6,617,256...6,665,179
Ensembl chr 3:6,615,343...6,822,817

G

cytochrome P450 family 3 subfamily A member 29

affects expression

flunixin meglumine affects the expression of CYP3A29 mRNA

NCBI chr 3:6,738,502...6,778,121
Ensembl chr 3:6,738,486...6,778,944

G

sulfotransferase family 1A member 3

affects expression

flunixin meglumine affects the expression of SULT1A1 mRNA

NCBI chr 3:18,351,205...18,354,653
Ensembl chr 3:18,351,194...18,354,649

gabapentin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

calcium voltage-gated channel auxiliary subunit alpha2delta 1

affects binding

Gabapentin binds to CACNA2D1 protein

NCBI chr 9:97,781,057...98,265,925
Ensembl chr 9:97,781,090...98,266,969

glyburide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

endothelin 1

multiple interactions

Glyburide inhibits the reaction [Carvedilol results in decreased expression of EDN1 protein]

NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348

glycerol 2-phosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alkaline phosphatase, biomineralization associated

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA

NCBI chr 6:79,589,695...79,649,646
Ensembl chr 6:79,589,045...79,649,644

G

BCL2 like 1

multiple interactions

[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of BCL2L1 mRNA

NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,143...35,414,694

G

caspase 3

multiple interactions

[Troglitazone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CASP3 mRNA

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

CCAAT enhancer binding protein alpha

multiple interactions

[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CEBPA mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CEBPA mRNA]

NCBI chr 6:43,083,200...43,085,884
Ensembl chr 6:43,083,207...43,085,836

G

collagen type I alpha 1 chain

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL1A1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL1A1 mRNA

NCBI chr12:26,379,087...26,397,180
Ensembl chr12:26,379,090...26,397,004

G

catenin beta 1

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA]

NCBI chr13:25,163,550...25,208,314
Ensembl chr13:25,164,277...25,208,311

G

fatty acid binding protein 4

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA]

NCBI chr 4:55,096,400...55,101,209
Ensembl chr 4:55,096,404...55,101,896

G

insulin like growth factor 1

multiple interactions

[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1 mRNA]

NCBI chr 5:81,762,027...81,909,253
Ensembl chr 5:81,775,970...81,848,033

G

insulin like growth factor 1 receptor

multiple interactions

[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1R mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1R mRNA]

NCBI chr 1:137,383,623...137,691,038
Ensembl chr 1:137,387,825...137,691,058

G

peroxisome proliferator activated receptor gamma

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA]

NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944

G

RUNX family transcription factor 2

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA

NCBI chr 7:40,106,581...40,353,304
Ensembl chr 7:40,106,532...40,460,687

G

secreted phosphoprotein 1

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA]

NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340

glycine betaine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

activating transcription factor 4

multiple interactions

Betaine inhibits the reaction [Glyphosate results in increased expression of ATF4 mRNA]; Betaine inhibits the reaction [Glyphosate results in increased expression of ATF4 protein]

NCBI chr 5:8,742,964...8,745,752
Ensembl chr 5:8,742,967...8,745,368

G

activating transcription factor 6

multiple interactions

Betaine inhibits the reaction [Glyphosate results in increased expression of ATF6 mRNA]

NCBI chr 4:88,591,279...88,806,156
Ensembl chr 4:88,591,288...88,805,304

G

BCL2 associated X, apoptosis regulator

multiple interactions

[Betaine co-treated with Glyphosate] results in increased expression of BAX mRNA

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140

G

caspase 3

multiple interactions

Betaine inhibits the reaction [Glyphosate results in increased expression of CASP3 mRNA]

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

caspase 9

multiple interactions

Betaine inhibits the reaction [Glyphosate results in increased expression of CASP9 mRNA]

NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007

G

catalase

multiple interactions

[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] promotes the reaction [bisphenol A results in decreased expression of CAT protein]; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT mRNA; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT protein; Betaine inhibits the reaction [Glyphosate results in increased expression of CAT mRNA]

PMID:29129240 PMID:36584959

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

claudin 1

multiple interactions

Betaine inhibits the reaction [Glyphosate results in decreased expression of CLDN1 mRNA]; Betaine inhibits the reaction [Glyphosate results in decreased expression of CLDN1 protein]

NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657

G

DNA damage inducible transcript 3

multiple interactions

Betaine inhibits the reaction [Glyphosate results in increased expression of DDIT3 mRNA]

NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829

G

DNA methyltransferase 1

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT1 mRNA

NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844

G

DNA methyltransferase 3 alpha

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of DNMT3A mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT3A mRNA

NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,603,087

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

Betaine inhibits the reaction [Glyphosate results in increased expression of EIF2AK3 mRNA]; Betaine inhibits the reaction [Glyphosate results in increased expression of EIF2AK3 protein]

NCBI chr 3:57,423,894...57,506,247
Ensembl chr 3:57,423,943...57,506,245

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions

Betaine inhibits the reaction [Glyphosate results in increased expression of EIF2S1 mRNA]; Betaine inhibits the reaction [Glyphosate results in increased expression of EIF2S1 protein]

NCBI chr 7:91,085,025...91,109,835
Ensembl chr 7:91,085,335...91,109,827

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

Betaine inhibits the reaction [Glyphosate results in increased expression of ERN1 mRNA]

NCBI chr12:14,881,913...14,963,290
Ensembl chr12:14,881,923...14,963,284

G

glutathione peroxidase 1

multiple interactions

[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of GPX1 mRNA; [bisphenol A co-treated with [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12]] results in increased expression of GPX1 mRNA

NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433

G

glutathione peroxidase 2

multiple interactions

[Betaine co-treated with Glyphosate] results in increased expression of GPX2 mRNA

NCBI chr 7:89,007,636...89,011,620
Ensembl chr 7:89,007,375...89,011,620

G

glycogen synthase 1

multiple interactions

[Betaine co-treated with Choline co-treated with Folic Acid co-treated with bisphenol A] results in increased methylation of GYS1 promoter; [Betaine co-treated with Choline co-treated with Folic Acid] results in decreased expression of GYS1 mRNA; [Betaine co-treated with Choline co-treated with Folic Acid] results in increased methylation of GYS1 promoter

NCBI chr 6:54,234,600...54,250,211
Ensembl chr 6:54,233,050...54,250,261

G

heat shock protein 90 beta family member 1

multiple interactions

Betaine inhibits the reaction [Glyphosate results in increased expression of HSP90B1 mRNA]; Betaine inhibits the reaction [Glyphosate results in increased expression of HSP90B1 protein]

NCBI chr 5:80,511,513...80,531,016
Ensembl chr 5:80,511,506...80,530,991

G

lactate dehydrogenase A

multiple interactions

[bisphenol A co-treated with Choline co-treated with Folic Acid co-treated with Betaine] results in decreased methylation of LDHA promoter

NCBI chr 2:40,814,163...40,827,284
Ensembl chr 2:40,814,169...40,826,715

G

mitofusin 1

multiple interactions

Betaine inhibits the reaction [Glyphosate results in increased expression of MFN1 mRNA]

NCBI chr13:117,404,637...117,441,750
Ensembl chr13:117,404,699...117,442,481

G

methylenetetrahydrofolate reductase

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of MTHFR mRNA

NCBI chr 6:71,863,637...71,882,118
Ensembl chr 6:71,863,637...71,881,820

G

NFE2 like bZIP transcription factor 2

multiple interactions

Betaine inhibits the reaction [Glyphosate results in increased expression of NFE2L2 mRNA]

NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

Betaine inhibits the reaction [Glyphosate results in increased expression of NQO1 mRNA]

NCBI chr 6:17,292,962...17,302,593
Ensembl chr 6:17,292,770...17,302,590

G

proliferating cell nuclear antigen

multiple interactions

Betaine inhibits the reaction [Glyphosate results in increased expression of PCNA mRNA]; Betaine inhibits the reaction [Glyphosate results in increased expression of PCNA protein]

NCBI chr17:14,137,746...14,142,584
Ensembl chr17:14,136,886...14,142,744

G

succinate dehydrogenase complex flavoprotein subunit A

multiple interactions

Betaine inhibits the reaction [Glyphosate results in increased expression of SDHA mRNA]

NCBI chr16:79,838,442...79,862,956
Ensembl chr16:79,834,044...79,862,524

G

sucrase-isomaltase

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SI mRNA

NCBI chr13:104,296,281...104,379,558
Ensembl chr13:104,296,283...104,379,478

G

solute carrier family 15 member 1

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of SLC15A1 mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased methylation of SLC15A1 promoter]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC15A1 mRNA

NCBI chr11:67,652,808...67,690,457
Ensembl chr11:67,652,193...67,710,933

G

solute carrier family 5 member 1

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with bisphenol A] results in increased expression of SLC5A1 mRNA; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC5A1 mRNA

NCBI chr14:48,566,400...48,704,145
Ensembl chr14:48,628,224...48,705,841

G

superoxide dismutase 1

multiple interactions

[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of SOD1 mRNA

NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729

G

superoxide dismutase 2

multiple interactions

Betaine inhibits the reaction [Glyphosate results in increased expression of SOD2 mRNA]

NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560

G

ubiquinol-cytochrome c reductase binding protein

multiple interactions

[Betaine co-treated with Glyphosate] results in decreased expression of UQCRB mRNA

NCBI chr 4:40,403,272...40,409,080
Ensembl chr 4:40,403,109...40,409,057

G

X-box binding protein 1

multiple interactions

Betaine inhibits the reaction [Glyphosate results in increased expression of XBP1 mRNA]

NCBI chr14:46,011,239...46,016,526
Ensembl chr14:46,008,377...46,016,526

hydrogen peroxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldehyde dehydrogenase 7 family member A1

decreases activity
multiple interactions

Hydrogen Peroxide results in decreased activity of ALDH7A1 protein
Dithiothreitol inhibits the reaction [Hydrogen Peroxide results in decreased activity of ALDH7A1 protein]; Mercaptoethanol inhibits the reaction [Hydrogen Peroxide results in decreased activity of ALDH7A1 protein]; NAD promotes the reaction [Hydrogen Peroxide results in decreased activity of ALDH7A1 protein]

NCBI chr 2:129,663,226...129,709,728
Ensembl chr 2:129,662,969...129,709,705

G

ATR serine/threonine kinase

multiple interactions
decreases expression

Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in decreased expression of ATR mRNA]

NCBI chr13:83,175,515...83,289,986
Ensembl chr13:83,174,824...83,289,989

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX mRNA]

PMID:37706587 PMID:38438008

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140

G

BCL2 apoptosis regulator

multiple interactions
decreases expression

Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 mRNA]

PMID:37706587 PMID:38438008

NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879

G

BCL3 transcription coactivator

decreases expression
multiple interactions

Hydrogen Peroxide results in decreased expression of BCL3 mRNA
Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL3 mRNA]

NCBI chr 6:51,256,033...51,264,923
Ensembl chr 6:51,256,033...51,265,351

G

caspase 3

multiple interactions
increases expression
increases activity

Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP3 mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP3 mRNA]; Sodium Selenite inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]; theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP3 mRNA]

PMID:15191356 PMID:37706587 PMID:38438008

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

catalase

decreases response to substance
multiple interactions

CAT results in decreased susceptibility to Hydrogen Peroxide
CAT protein inhibits the reaction [Paraquat results in increased abundance of Hydrogen Peroxide]

PMID:11039594 PMID:18086661

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

C-C motif chemokine ligand 20

increases expression
multiple interactions

Hydrogen Peroxide results in increased expression of CCL20 mRNA
Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of CCL20 mRNA]

NCBI chr15:129,172,743...129,176,069

G

cyclin E1

multiple interactions
increases expression

Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of CCNE1 mRNA]

NCBI chr 6:39,919,541...39,933,224
Ensembl chr 6:39,919,624...39,933,363

G

claudin 1

decreases expression
multiple interactions

Hydrogen Peroxide results in decreased expression of CLDN1 mRNA; Hydrogen Peroxide results in decreased expression of CLDN1 protein
SB 203580 inhibits the reaction [Hydrogen Peroxide results in decreased expression of CLDN1 mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in decreased expression of CLDN1 protein]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of CLDN1 mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of CLDN1 protein]

NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657

G

C-X-C motif chemokine ligand 8

increases expression

Hydrogen Peroxide results in increased expression of CXCL8 mRNA

NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861

G

dual specificity phosphatase 1

multiple interactions
increases expression

Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of DUSP1 mRNA]

NCBI chr16:51,457,924...51,461,095
Ensembl chr16:51,458,020...51,461,086

G

dual specificity phosphatase 10

increases expression
multiple interactions

Hydrogen Peroxide results in increased expression of DUSP10 mRNA
Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of DUSP10 mRNA]

NCBI chr10:10,866,446...10,905,852
Ensembl chr10:10,866,448...10,905,857

G

endothelin 1

multiple interactions
increases expression

Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of EDN1 mRNA]

NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348

G

epidermal growth factor receptor

multiple interactions
decreases expression

Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in decreased expression of EGFR mRNA]

NCBI chr 9:139,302,410...139,474,632
Ensembl chr 9:139,300,022...139,475,589

G

fibroblast growth factor 18

increases expression
multiple interactions

Hydrogen Peroxide results in increased expression of FGF18 mRNA
Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of FGF18 mRNA]

NCBI chr16:52,724,867...52,760,246
Ensembl chr16:52,725,356...52,759,791

G

fibroblast growth factor 8

increases expression
multiple interactions

Hydrogen Peroxide results in increased expression of FGF8 mRNA
Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of FGF8 mRNA]

NCBI chr14:112,808,215...112,814,225
Ensembl chr14:112,808,162...112,814,248

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression
multiple interactions

Hydrogen Peroxide results in increased expression of FOS mRNA
Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of FOS mRNA]

PMID:18086661 PMID:37706587

NCBI chr 7:98,449,508...98,451,971
Ensembl chr 7:98,449,349...98,455,554

G

growth arrest and DNA damage inducible beta

increases expression
multiple interactions

Hydrogen Peroxide results in increased expression of GADD45B mRNA
Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of GADD45B mRNA]

NCBI chr 2:76,107,928...76,111,458
Ensembl chr 2:76,107,929...76,111,479

G

growth arrest and DNA damage inducible gamma

multiple interactions
increases expression

Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of GADD45G mRNA]

NCBI chr14:1,166,000...1,167,538
Ensembl chr14:1,165,982...1,167,529

G

heat shock protein family A (Hsp70) member 1 like

increases expression
multiple interactions

Hydrogen Peroxide results in increased expression of HSPA1L mRNA
Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of HSPA1L mRNA]

NCBI chr 7:23,909,960...23,938,678
Ensembl chr 7:23,909,960...23,914,629

G

heat shock protein family A (Hsp70) member 5

increases expression
multiple interactions

Hydrogen Peroxide results in increased expression of HSPA5 protein
Aspirin inhibits the reaction [Hydrogen Peroxide results in increased expression of HSPA5 protein]; nimesulide inhibits the reaction [Hydrogen Peroxide results in increased expression of HSPA5 protein]

NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894

G

insulin like growth factor 1 receptor

decreases expression
multiple interactions

Hydrogen Peroxide results in decreased expression of IGF1R mRNA
Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in decreased expression of IGF1R mRNA]

NCBI chr 1:137,383,623...137,691,038
Ensembl chr 1:137,387,825...137,691,058

G

interleukin 15

increases expression
multiple interactions

Hydrogen Peroxide results in increased expression of IL15 mRNA
Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of IL15 mRNA]

NCBI chr 8:85,666,963...85,740,980
Ensembl chr 8:85,667,321...85,678,461

G

interleukin 6

multiple interactions
increases expression

SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of IL6 mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of IL6 mRNA]

NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression
multiple interactions

Hydrogen Peroxide results in increased expression of JUN mRNA; Hydrogen Peroxide results in increased expression of JUN protein
Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of JUN mRNA]; Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of JUN protein]

NCBI chr 6:153,686,425...153,687,635
Ensembl chr 6:153,685,682...153,687,636

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of JUNB mRNA]

NCBI chr 2:66,214,086...66,219,435
Ensembl chr 2:66,214,138...66,217,002

G

lactate dehydrogenase A

multiple interactions
increases activity

SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased activity of LDHA protein]; theanine inhibits the reaction [Hydrogen Peroxide results in increased activity of LDHA protein]

NCBI chr 2:40,814,163...40,827,284
Ensembl chr 2:40,814,169...40,826,715

G

LIF interleukin 6 family cytokine

increases expression
multiple interactions

Hydrogen Peroxide results in increased expression of LIF mRNA
Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of LIF mRNA]

NCBI chr14:47,221,540...47,239,513
Ensembl chr14:47,221,560...47,238,749

G

interleukin-1 beta-like

multiple interactions
increases expression

SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of IL1B mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of IL1B protein]; theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of IL1B mRNA]

G

mitogen-activated protein kinase kinase 4

multiple interactions

[Oleanolic Acid co-treated with Hydrogen Peroxide] results in increased expression of MAP2K4 mRNA

NCBI chr12:56,402,029...56,516,217
Ensembl chr12:56,402,075...56,516,238

G

mitogen-activated protein kinase kinase kinase 5

multiple interactions

[Oleanolic Acid co-treated with Hydrogen Peroxide] results in increased expression of MAP3K5 mRNA

NCBI chr 1:27,380,143...27,600,500
Ensembl chr 1:27,380,142...27,600,493

G

mitogen-activated protein kinase 1

multiple interactions
increases phosphorylation

3,4-dihydroxyphenylethanol inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]

PMID:11325585 PMID:21798251

NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513

G

mitogen-activated protein kinase 14

increases expression
multiple interactions

Hydrogen Peroxide results in increased expression of MAPK14 protein
theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of MAPK14 protein]

NCBI chr 7:31,791,398...31,861,544
Ensembl chr 7:31,790,877...31,862,031

G

mitogen-activated protein kinase 3

increases phosphorylation
multiple interactions

Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein
3,4-dihydroxyphenylethanol inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]

PMID:11325585 PMID:21798251

NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567

G

mitogen-activated protein kinase 8

increases phosphorylation

Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein

PMID:11325585 PMID:18086661

NCBI chr14:88,988,914...89,108,875
Ensembl chr14:88,988,949...89,108,874

G

mitogen-activated protein kinase 9

increases phosphorylation

Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein

NCBI chr 2:78,338,466...78,399,108
Ensembl chr 2:78,338,376...78,399,100

G

matrix metallopeptidase 14

multiple interactions
increases expression

Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of MMP14 mRNA]

NCBI chr 7:76,174,502...76,185,931
Ensembl chr 7:76,172,971...76,185,928

G

NFKB inhibitor alpha

increases expression
multiple interactions

Hydrogen Peroxide results in increased expression of NFKBIA mRNA
Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of NFKBIA mRNA]

NCBI chr 7:64,508,119...64,510,754
Ensembl chr 7:64,507,822...64,511,277

G

occludin

decreases expression
multiple interactions

Hydrogen Peroxide results in decreased expression of OCLN mRNA; Hydrogen Peroxide results in decreased expression of OCLN protein
SB 203580 inhibits the reaction [Hydrogen Peroxide results in decreased expression of OCLN mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in decreased expression of OCLN protein]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of OCLN mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of OCLN protein]

NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033

G

protein phosphatase, Mg2+/Mn2+ dependent 1D

increases expression
multiple interactions

Hydrogen Peroxide results in increased expression of PPM1D mRNA
Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of PPM1D mRNA]

NCBI chr12:37,485,601...37,536,159
Ensembl chr12:37,485,588...37,536,146

G

RELA proto-oncogene, NF-kB subunit

increases phosphorylation
multiple interactions

Hydrogen Peroxide results in increased phosphorylation of RELA protein
theanine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of RELA protein]

NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469

G

suppressor of cytokine signaling 3

increases expression
multiple interactions

Hydrogen Peroxide results in increased expression of SOCS3 mRNA
Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of SOCS3 mRNA]

NCBI chr12:3,643,832...3,647,015
Ensembl chr12:3,643,929...3,647,009

G

superoxide dismutase 1

multiple interactions

[sodium arsenite results in increased activity of SOD1 protein] which results in increased abundance of Hydrogen Peroxide

NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729

G

tight junction protein 1

multiple interactions
decreases expression

SB 203580 inhibits the reaction [Hydrogen Peroxide results in decreased expression of TJP1 mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in decreased expression of TJP1 protein]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of TJP1 mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of TJP1 protein]
Hydrogen Peroxide results in decreased expression of TJP1 mRNA; Hydrogen Peroxide results in decreased expression of TJP1 protein

NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836

G

tumor necrosis factor

increases expression
multiple interactions

Hydrogen Peroxide results in increased expression of TNF mRNA
SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of TNF protein]; theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of TNF mRNA]

PMID:22083491 PMID:38438008

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416

G

TNF alpha induced protein 3

multiple interactions
increases expression

Oleanolic Acid inhibits the reaction [Hydrogen Peroxide results in increased expression of TNFAIP3 mRNA]

NCBI chr 1:26,474,158...26,489,771
Ensembl chr 1:26,473,938...26,489,822

G

xanthine dehydrogenase

multiple interactions

[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Hydrogen Peroxide

NCBI chr 3:107,987,060...108,052,043
Ensembl chr 3:107,987,126...108,053,169

hydroxytyrosol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

mitogen-activated protein kinase 1

multiple interactions

3,4-dihydroxyphenylethanol inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]

NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513

G

mitogen-activated protein kinase 3

multiple interactions

3,4-dihydroxyphenylethanol inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]

NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567

hypoxanthine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catalase

multiple interactions

CAT protein inhibits the reaction [[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide]; CAT protein results in decreased activity of [Hypoxanthine co-treated with XDH protein]

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

xanthine dehydrogenase

multiple interactions

[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide; [Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Hydrogen Peroxide; [Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Superoxides; CAT protein inhibits the reaction [[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide]; CAT protein results in decreased activity of [Hypoxanthine co-treated with XDH protein]; tempol inhibits the reaction [[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide]; tempol results in decreased activity of [Hypoxanthine co-treated with XDH protein]

NCBI chr 3:107,987,060...108,052,043
Ensembl chr 3:107,987,126...108,053,169

L-glutamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interleukin 10

multiple interactions

Glutamine inhibits the reaction [bisphenol A results in decreased secretion of IL10 protein]

NCBI chr 9:67,400,727...67,405,941
Ensembl chr 9:67,400,728...67,405,378

G

interleukin 6

multiple interactions

Glutamine inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]; Glutamine inhibits the reaction [bisphenol A results in increased secretion of IL6 protein]

NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263

G

interleukin-1 beta-like

multiple interactions

Glutamine inhibits the reaction [bisphenol A results in increased secretion of IL1B protein]

G

MYD88 innate immune signal transduction adaptor

multiple interactions

Glutamine inhibits the reaction [bisphenol A results in increased expression of MYD88 mRNA]

NCBI chr13:22,976,951...22,979,568
Ensembl chr13:22,966,137...22,983,109

G

nuclear factor kappa B subunit 1

multiple interactions

Glutamine inhibits the reaction [bisphenol A results in increased expression of NFKB1 mRNA]

NCBI chr 8:118,391,010...118,478,927
Ensembl chr 8:118,390,638...118,506,691

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Glutamine inhibits the reaction [bisphenol A results in increased expression of RELA protein]

NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469

G

trefoil factor 3

multiple interactions

Glutamine inhibits the reaction [bisphenol A results in decreased expression of TFF3 protein]

NCBI chr13:205,641,038...205,644,333
Ensembl chr13:205,641,038...205,644,333

G

toll like receptor 4

multiple interactions

Glutamine inhibits the reaction [bisphenol A results in increased expression of TLR4 mRNA]; Glutamine inhibits the reaction [bisphenol A results in increased expression of TLR4 protein]

NCBI chr 1:258,044,610...258,054,641
Ensembl chr 1:258,044,610...258,058,970

G

tumor necrosis factor

multiple interactions

Glutamine inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; Glutamine inhibits the reaction [bisphenol A results in increased secretion of TNF protein]

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416

malathion

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 2

increases expression

Malathion results in increased expression of AKT2 mRNA

NCBI chr 6:48,555,785...48,620,472
Ensembl chr 6:48,555,795...48,587,919

G

BCL2 associated X, apoptosis regulator

increases expression

Malathion results in increased expression of BAX mRNA

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140

G

BCL2 apoptosis regulator

decreases expression
multiple interactions

Malathion results in decreased expression of BCL2 mRNA
Melatonin inhibits the reaction [Malathion results in decreased expression of BCL2 mRNA]

NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879

G

catalase

decreases expression
multiple interactions

Malathion results in decreased expression of CAT mRNA
Melatonin inhibits the reaction [Malathion results in decreased expression of CAT mRNA]

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

cytochrome P450 family 1 subfamily A member 1

decreases expression

Malathion results in decreased expression of CYP1A1 mRNA

NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775

G

cytochrome P450 family 1 subfamily B member 1

decreases expression

Malathion results in decreased expression of CYP1B1 mRNA

NCBI chr 3:102,195,743...102,205,687
Ensembl chr 3:102,195,741...102,205,683

G

dual oxidase 2

decreases expression

Malathion results in decreased expression of DUOX2 mRNA

NCBI chr 1:126,620,468...126,641,406
Ensembl chr 1:126,620,510...126,641,406

G

glutathione peroxidase 4

increases expression

Malathion results in increased expression of GPX4 mRNA

NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,931

G

glutathione peroxidase 6

increases expression

Malathion results in increased expression of GPX6 mRNA

NCBI chr 7:22,256,013...22,267,992
Ensembl chr 7:22,256,038...22,267,992

G

glutathione S-transferase alpha M14

decreases expression

Malathion results in decreased expression of GSTA1 mRNA

NCBI chr 7:46,553,813...46,567,596

G

mitochondrially encoded cytochrome c oxidase I

affects expression

Malathion affects the expression of COX1 mRNA

NCBI chr MT:6,511...8,055
Ensembl chr MT:6,511...8,055

G

mitochondrially encoded cytochrome c oxidase III

affects expression

Malathion affects the expression of COX3 mRNA

NCBI chr MT:9,800...10,583
Ensembl chr MT:9,800...10,583

G

perilipin 2

multiple interactions
decreases expression

Melatonin inhibits the reaction [Malathion results in decreased expression of PLIN2 mRNA]; Melatonin inhibits the reaction [Malathion results in decreased expression of PLIN2 protein]
Malathion results in decreased expression of PLIN2 mRNA; Malathion results in decreased expression of PLIN2 protein

NCBI chr 1:203,683,867...203,709,277
Ensembl chr 1:203,683,862...203,709,273

G

peroxisome proliferator activated receptor gamma

multiple interactions
decreases expression

Melatonin inhibits the reaction [Malathion results in decreased expression of PPARG mRNA]; Melatonin inhibits the reaction [Malathion results in decreased expression of PPARG protein]
Malathion results in decreased expression of PPARG mRNA; Malathion results in decreased expression of PPARG protein

NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944

G

solute carrier family 34 member 2

increases expression

Malathion results in increased expression of SLC34A2 mRNA

NCBI chr 8:19,481,127...19,507,903
Ensembl chr 8:19,481,198...19,509,666

G

superoxide dismutase 2

increases expression

Malathion results in increased expression of SOD2 mRNA

NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560

G

sorbitol dehydrogenase

increases expression

Malathion results in increased expression of SORD mRNA

NCBI chr 1:126,659,198...126,701,084
Ensembl chr 1:126,655,156...126,701,138

G

tumor protein p53

increases expression
multiple interactions

Malathion results in increased expression of TP53 mRNA
Melatonin inhibits the reaction [Malathion results in increased expression of TP53 mRNA]

NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818

methoctramine tetrahydrochloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cholinergic receptor muscarinic 2

multiple interactions

methoctramine inhibits the reaction [Quinuclidinyl Benzilate binds to CHRM2 protein]

NCBI chr18:12,455,139...12,600,314
Ensembl chr18:12,455,145...12,600,186

methylglyoxal

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutamic-oxaloacetic transaminase 1

affects glycation
affects folding
decreases activity

Pyruvaldehyde affects the glycation of GOT1 protein
Pyruvaldehyde affects the folding of GOT1 protein
Pyruvaldehyde results in decreased activity of GOT1 protein

NCBI chr14:110,608,422...110,635,825
Ensembl chr14:110,608,430...110,635,874

mogroside V

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interleukin 18

multiple interactions

mogroside V inhibits the reaction [Particulate Matter results in increased expression of IL18 mRNA]

NCBI chr 9:39,839,959...39,861,258
Ensembl chr 9:39,834,973...39,861,219

G

interleukin-1 beta-like

increases expression

mogroside V results in increased expression of IL1B mRNA

G

NLR family pyrin domain containing 3

multiple interactions

mogroside V inhibits the reaction [Particulate Matter results in increased expression of NLRP3 protein]

NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228

G

nitric oxide synthase 2

multiple interactions

mogroside V inhibits the reaction [Particulate Matter results in increased expression of NOS2 mRNA]

NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146

G

prostaglandin-endoperoxide synthase 2

multiple interactions

mogroside V inhibits the reaction [Particulate Matter results in increased expression of PTGS2 mRNA]

NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

mogroside V inhibits the reaction [Particulate Matter results in increased phosphorylation of RELA protein]

NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469

G

tumor necrosis factor

multiple interactions

mogroside V inhibits the reaction [Particulate Matter results in increased expression of TNF mRNA]

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416

monosodium L-glutamate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase alpha

increases expression
multiple interactions

Sodium Glutamate results in increased expression of ACACA mRNA
Dietary Fats inhibits the reaction [Sodium Glutamate results in increased expression of ACACA mRNA]

NCBI chr12:38,580,916...38,875,067
Ensembl chr12:38,581,457...38,824,712

G

acyl-CoA oxidase 1

increases expression

Sodium Glutamate results in increased expression of ACOX1 mRNA

NCBI chr12:5,450,913...5,479,550
Ensembl chr12:5,439,361...5,479,546

G

fatty acid synthase

multiple interactions
increases expression

Dietary Fats inhibits the reaction [Sodium Glutamate results in increased expression of FASN mRNA]

NCBI chr12:922,405...937,560
Ensembl chr12:920,509...937,561

G

free fatty acid receptor 2

multiple interactions
affects expression

Dietary Fats affects the reaction [Sodium Glutamate affects the expression of FFAR2 mRNA]; Sodium Glutamate affects the reaction [Dietary Fats affects the expression of FFAR2 mRNA]

NCBI chr 6:44,899,879...44,904,461
Ensembl chr 6:44,901,159...44,904,459

G

free fatty acid receptor 4

affects expression
multiple interactions

Sodium Glutamate affects the expression of FFAR4 mRNA
Dietary Fats affects the reaction [Sodium Glutamate affects the expression of FFAR4 mRNA]; Sodium Glutamate affects the reaction [Dietary Fats affects the expression of FFAR4 mRNA]

Ensembl chr14:105,011,942...105,037,498

G

G protein-coupled receptor 119

affects expression
multiple interactions

Sodium Glutamate affects the expression of GPR119 mRNA
Dietary Fats affects the reaction [Sodium Glutamate affects the expression of GPR119 mRNA]; Sodium Glutamate affects the reaction [Dietary Fats affects the expression of GPR119 mRNA]

NCBI chr X:106,872,225...106,873,299
Ensembl chr X:106,872,225...106,873,299

G

liver carboxylesterase-like

multiple interactions

Sodium Glutamate inhibits the reaction [Dietary Fats results in decreased expression of CES1 mRNA]

G

patatin like phospholipase domain containing 2

increases expression

Sodium Glutamate results in increased expression of PNPLA2 mRNA

NCBI chr 2:513,065...517,962
Ensembl chr 2:513,077...518,182

G

sterol regulatory element binding transcription factor 1

multiple interactions
increases expression

Dietary Fats inhibits the reaction [Sodium Glutamate results in increased expression of SREBF1 mRNA]

NCBI chr12:60,733,967...60,750,951
Ensembl chr12:60,733,907...60,751,267

N(5)-ethyl-L-glutamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX mRNA]

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140

G

BCL2 apoptosis regulator

multiple interactions

theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 mRNA]

NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879

G

caspase 3

multiple interactions

theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP3 mRNA]

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

claudin 1

multiple interactions

[N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of CLDN1 mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of CLDN1 protein]; theanine inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]

PMID:37271275 PMID:38438008

NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657

G

interleukin 6

multiple interactions

theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of IL6 mRNA]

NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263

G

lactate dehydrogenase A

multiple interactions

theanine inhibits the reaction [Hydrogen Peroxide results in increased activity of LDHA protein]

NCBI chr 2:40,814,163...40,827,284
Ensembl chr 2:40,814,169...40,826,715

G

interleukin-1 beta-like

multiple interactions

[N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of IL1B mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]

PMID:37271275 PMID:38438008

G

mitogen-activated protein kinase 14

multiple interactions

[SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK14 mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of MAPK14 protein]; theanine inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK14 mRNA]

PMID:37271275 PMID:38438008

NCBI chr 7:31,791,398...31,861,544
Ensembl chr 7:31,790,877...31,862,031

G

NLR family pyrin domain containing 3

multiple interactions

[N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]

NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228

G

occludin

multiple interactions

[N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of OCLN mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of OCLN protein]; theanine inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]

PMID:37271275 PMID:38438008

NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

theanine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of RELA protein]

NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469

G

tight junction protein 1

multiple interactions

theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of TJP1 mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of TJP1 protein]

NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836

G

tumor necrosis factor

multiple interactions

theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of TNF mRNA]

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416

NAD(+)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldehyde dehydrogenase 7 family member A1

multiple interactions

NAD promotes the reaction [Hydrogen Peroxide results in decreased activity of ALDH7A1 protein]

NCBI chr 2:129,663,226...129,709,728
Ensembl chr 2:129,662,969...129,709,705

neomycin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 5 member 1

decreases expression

Neomycin results in decreased expression of SLC5A1 mRNA; Neomycin results in decreased expression of SLC5A1 protein

NCBI chr14:48,566,400...48,704,145
Ensembl chr14:48,628,224...48,705,841

nicotinamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

forkhead box O1

increases expression

Niacinamide results in increased expression of FOXO1 mRNA

NCBI chr11:15,317,222...15,410,059
Ensembl chr11:15,317,124...15,410,473

G

peroxisome proliferator activated receptor gamma

increases expression

Niacinamide results in increased expression of PPARG mRNA

NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944

G

sirtuin 1

decreases expression

Niacinamide results in decreased expression of SIRT1 mRNA

NCBI chr14:71,091,167...71,126,351
Ensembl chr14:71,091,167...71,123,297

nitroglycerin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

protein kinase cGMP-dependent 1

multiple interactions
increases activity
affects expression

Superoxides affects the reaction [Nitroglycerin results in increased activity of PRKG1 protein]
Nitroglycerin affects the expression of PRKG1 mRNA; Nitroglycerin affects the expression of PRKG1 protein

NCBI chr14:97,558,531...98,793,080
Ensembl chr14:97,558,533...98,793,010

notoginsenoside R1

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interleukin 10

decreases expression

notoginsenoside R1 results in decreased expression of IL10 protein

NCBI chr 9:67,400,727...67,405,941
Ensembl chr 9:67,400,728...67,405,378

G

interleukin 4

decreases expression

notoginsenoside R1 results in decreased expression of IL4 protein

NCBI chr 2:134,986,817...134,994,365
Ensembl chr 2:134,986,817...134,994,365

O-acetyl-L-carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 5

increases uptake

SLC22A5 protein results in increased uptake of Acetylcarnitine

NCBI chr 2:134,660,741...134,847,575
Ensembl chr 2:134,660,808...134,686,219

ochratoxin A

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

decreases phosphorylation

ochratoxin A results in decreased phosphorylation of AKT1 protein

G

annexin A5

decreases expression

ochratoxin A results in decreased expression of ANXA5 mRNA

NCBI chr 8:102,387,833...102,420,868
Ensembl chr 8:102,388,103...102,425,750

G

apoptotic peptidase activating factor 1

increases expression
multiple interactions

ochratoxin A results in increased expression of APAF1 mRNA; ochratoxin A results in increased expression of APAF1 protein
fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of APAF1 protein]

NCBI chr 5:85,166,616...85,258,751
Ensembl chr 5:85,166,628...85,258,364

G

autophagy related 5

multiple interactions
increases expression

ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]
ochratoxin A results in increased expression of ATG5 protein

PMID:28699257 PMID:30287338

NCBI chr 1:72,343,950...72,520,402
Ensembl chr 1:72,270,799...72,520,396

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of BAX protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA]
ochratoxin A results in increased expression of BAX mRNA; ochratoxin A results in increased expression of BAX protein

PMID:33905761 PMID:36397609

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140

G

BCL2 apoptosis regulator

multiple interactions
decreases expression
affects expression

[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in decreased expression of BCL2 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA]; TLR4 protein affects the reaction [ochratoxin A affects the expression of BCL2 mRNA]
ochratoxin A results in decreased expression of BCL2 mRNA; ochratoxin A results in decreased expression of BCL2 protein

PMID:28528741 PMID:29080797 PMID:33905761 PMID:36397609

NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879

G

beclin 1

multiple interactions
increases expression

BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]
ochratoxin A results in increased expression of BECN1 protein

NCBI chr12:20,041,914...20,054,249
Ensembl chr12:20,041,956...20,054,373

G

BRCA1 DNA repair associated

increases expression

ochratoxin A results in increased expression of BRCA1 protein

NCBI chr12:19,788,087...19,854,515
Ensembl chr12:19,786,020...19,854,668

G

caspase 1, apoptosis-related cysteine peptidase

multiple interactions

Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein]; ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein; Taurine inhibits the reaction [ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein]

NCBI chr 9:35,188,066...35,199,364
Ensembl chr 9:35,186,420...35,200,328

G

caspase 3

multiple interactions
increases expression
increases cleavage

3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; Chloroquine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP3 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein]
ochratoxin A results in increased expression of CASP3 mRNA; ochratoxin A results in increased expression of CASP3 protein; ochratoxin A results in increased expression of CASP3 protein modified form

PMID:30287338 PMID:33905761 PMID:36397609

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

caspase 9

multiple interactions
increases expression

[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein; [fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 mRNA]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein modified form]; fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CASP9 protein]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein modified form]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of CASP9 protein]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein]
ochratoxin A results in increased expression of CASP9 mRNA; ochratoxin A results in increased expression of CASP9 protein; ochratoxin A results in increased expression of CASP9 protein modified form

PMID:33905761 PMID:36397609

NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007

G

catalase

decreases expression
multiple interactions

ochratoxin A results in decreased expression of CAT mRNA; ochratoxin A results in decreased expression of CAT protein
Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of CAT mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of CAT mRNA]

PMID:18547704 PMID:36281498

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

crystallin alpha B

increases expression

ochratoxin A results in increased expression of CRYAB mRNA

NCBI chr 9:39,638,505...39,643,530
Ensembl chr 9:39,638,506...39,643,530

G

cytochrome c, somatic

multiple interactions
increases expression

fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of CYCS mRNA]

NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866

G

cytochrome P450 family 2 subfamily A member 19

decreases expression

ochratoxin A results in decreased expression of CYP2A6 mRNA

NCBI chr 6:49,056,579...49,064,111
Ensembl chr 6:49,056,578...49,064,107

G

defender against cell death 1

decreases expression

ochratoxin A results in decreased expression of DAD1 mRNA

NCBI chr 7:76,432,040...76,457,403
Ensembl chr 7:76,432,051...76,457,192

G

DNA methyltransferase 1

increases expression
multiple interactions

ochratoxin A results in increased expression of DNMT1 mRNA; ochratoxin A results in increased expression of DNMT1 protein
Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 protein]

PMID:29080797 PMID:30923867

NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844

G

DNA methyltransferase 3 alpha

increases expression

ochratoxin A results in increased expression of DNMT3A mRNA

PMID:29080797 PMID:30923867

NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,603,087

G

glutamate-cysteine ligase catalytic subunit

decreases expression
multiple interactions

ochratoxin A results in decreased expression of GCLC mRNA
ochratoxin A inhibits the reaction [sulforaphane results in increased expression of GCLC mRNA]

NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,565...27,253,530

G

glomulin, FKBP associated protein

increases expression

ochratoxin A results in increased expression of GLMN mRNA

NCBI chr 4:124,773,957...124,813,336
Ensembl chr 4:124,773,980...124,813,335

G

glutathione peroxidase 1

decreases expression
multiple interactions

ochratoxin A results in decreased expression of GPX1 mRNA
Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA]

NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433

G

glutathione peroxidase 4

decreases expression
multiple interactions

ochratoxin A results in decreased expression of GPX4 mRNA
Acetylcysteine inhibits the reaction [ochratoxin A results in decreased expression of GPX4 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of GPX4 mRNA]

NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,931

G

gasdermin D

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]

NCBI chr 4:995,753...1,001,964
Ensembl chr 4:995,763...1,000,271

G

H2A.X variant histone

multiple interactions
increases expression

alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in increased expression of H2AX protein]; Decitabine inhibits the reaction [ochratoxin A results in increased expression of H2AX protein]; STAT3 protein affects the reaction [ochratoxin A results in increased expression of H2AX protein]

PMID:30923867 PMID:32454083

NCBI chr 9:46,308,824...46,310,494
Ensembl chr 9:46,309,653...46,310,084

G

hepatitis A virus cellular receptor 1

multiple interactions

[fumonisin B1 co-treated with ochratoxin A] results in increased expression of HAVCR1 mRNA

NCBI chr16:66,162,318...66,208,868

G

histone deacetylase 1

multiple interactions
increases expression

Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 mRNA]; Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 protein]
ochratoxin A results in increased expression of HDAC1 mRNA; ochratoxin A results in increased expression of HDAC1 protein

NCBI chr 6:88,749,611...88,785,220
Ensembl chr 6:88,749,634...88,785,411

G

heat shock protein 90 beta family member 1

increases expression
decreases expression

ochratoxin A results in increased expression of HSP90B1 mRNA
ochratoxin A results in decreased expression of HSP90B1 mRNA

NCBI chr 5:80,511,513...80,531,016
Ensembl chr 5:80,511,506...80,530,991

G

heat shock protein family A (Hsp70) member 5

increases expression

ochratoxin A results in increased expression of HSPA5 mRNA; ochratoxin A results in increased expression of HSPA5 protein

NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894

G

heat shock protein family D (Hsp60) member 1

decreases expression

ochratoxin A results in decreased expression of HSPD1 mRNA

NCBI chr15:101,360,355...101,373,498
Ensembl chr15:101,360,094...101,373,526

G

inhibitor of DNA binding 2

decreases expression

ochratoxin A results in decreased expression of ID2 mRNA

NCBI chr 3:127,500,759...127,503,207
Ensembl chr 3:127,500,763...127,503,257

G

insulin like growth factor binding protein 2

increases expression

ochratoxin A results in increased expression of IGFBP2 mRNA

NCBI chr15:118,822,092...118,850,985
Ensembl chr15:118,822,047...118,850,976

G

interleukin 18

increases expression

ochratoxin A results in increased expression of IL18 protein

NCBI chr 9:39,839,959...39,861,258
Ensembl chr 9:39,834,973...39,861,219

G

interleukin 1 alpha

multiple interactions

ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]]

NCBI chr 3:43,718,320...43,731,668
Ensembl chr 3:43,718,368...43,731,119

G

interleukin 2

decreases secretion

ochratoxin A results in decreased secretion of IL2 protein

NCBI chr 8:101,640,938...101,645,683
Ensembl chr 8:101,640,944...101,645,609

G

interleukin 4

increases expression

ochratoxin A results in increased expression of IL4 mRNA

NCBI chr 2:134,986,817...134,994,365
Ensembl chr 2:134,986,817...134,994,365

G

interleukin 6

increases expression
multiple interactions

ochratoxin A results in increased expression of IL6 mRNA
NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of IL6 mRNA]

NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263

G

Janus kinase 2

multiple interactions
increases phosphorylation

Decitabine inhibits the reaction [ochratoxin A results in increased phosphorylation of JAK2 protein]

NCBI chr 1:216,849,744...217,002,310
Ensembl chr 1:216,848,689...217,002,148

G

lipocalin 2

multiple interactions

[fumonisin B1 co-treated with ochratoxin A] results in increased expression of LCN2 mRNA

NCBI chr 1:268,609,975...268,614,651
Ensembl chr 1:268,609,887...268,614,644

G

glutathione S-transferase alpha M14

decreases expression
multiple interactions

ochratoxin A results in decreased expression of GSTA1 mRNA
ochratoxin A inhibits the reaction [sulforaphane results in increased expression of GSTA1 mRNA]

NCBI chr 7:46,553,813...46,567,596

G

interleukin-1 beta-like

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of IL1B protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of IL1B protein]

G

mitogen-activated protein kinase 1

increases phosphorylation
multiple interactions

ochratoxin A results in increased phosphorylation of MAPK1 protein
ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]

PMID:28528741 PMID:28699257

NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation

ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]
ochratoxin A results in increased phosphorylation of MAPK3 protein

PMID:28528741 PMID:28699257

NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567

G

mechanistic target of rapamycin kinase

decreases phosphorylation

ochratoxin A results in decreased phosphorylation of MTOR protein

NCBI chr 6:71,286,989...71,412,913
Ensembl chr 6:71,286,989...71,412,888

G

MYD88 innate immune signal transduction adaptor

multiple interactions

ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of MYD88 mRNA]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of MYD88 protein]

NCBI chr13:22,976,951...22,979,568
Ensembl chr13:22,966,137...22,983,109

G

MYG1 exonuclease

decreases expression

ochratoxin A results in decreased expression of PFDN5 mRNA

NCBI chr 5:18,512,637...18,516,928
Ensembl chr 5:18,512,697...18,517,174

G

nei like DNA glycosylase 1

decreases expression
multiple interactions

ochratoxin A results in decreased expression of NEIL1 mRNA
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]

NCBI chr 7:58,261,761...58,269,001
Ensembl chr 7:58,261,769...58,268,522

G

nei like DNA glycosylase 3

multiple interactions
decreases expression

alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]

NCBI chr15:39,416,073...39,632,313
Ensembl chr15:39,581,856...39,632,308

G

NFE2 like bZIP transcription factor 2

decreases activity
multiple interactions
decreases expression

ochratoxin A results in decreased activity of NFE2L2 protein
NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of IL6 mRNA]; NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TP53 protein]; ochratoxin A inhibits the reaction [sulforaphane affects the localization of NFE2L2 protein]; ochratoxin A inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; ochratoxin A inhibits the reaction [sulforaphane results in increased expression of NFE2L2 mRNA]
ochratoxin A results in decreased expression of NFE2L2 mRNA

PMID:18547363 PMID:18547704 PMID:28710020

NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183

G

NLR family pyrin domain containing 3

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein]

NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228

G

nitric oxide synthase 2

increases expression
multiple interactions

ochratoxin A results in increased expression of INOS mRNA
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of INOS mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of INOS mRNA]

NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146

G

nucleophosmin 1

increases expression

ochratoxin A results in increased expression of NPM1 mRNA

NCBI chr16:52,767,263...52,781,862
Ensembl chr16:52,765,298...52,781,771

G

netrin 1

multiple interactions
increases expression

fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of NTN1 mRNA]

NCBI chr12:54,089,444...54,292,191
Ensembl chr12:54,089,472...54,292,193

G

8-oxoguanine DNA glycosylase

decreases expression
multiple interactions

ochratoxin A results in decreased expression of OGG1 mRNA
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]

NCBI chr13:66,038,669...66,045,478

G

poly(ADP-ribose) polymerase 1

increases cleavage
increases expression
multiple interactions

ochratoxin A results in increased cleavage of PARP1 protein
ochratoxin A results in increased expression of PARP1 protein
3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; ATG5 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; BECN1 protein affects the reaction [ochratoxin A results in increased cleavage of PARP1 protein]; Chloroquine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein]

PMID:30287338 PMID:32454083

NCBI chr10:14,203,157...14,241,164
Ensembl chr10:14,203,160...14,241,196

G

phosphoenolpyruvate carboxykinase 1

decreases expression

ochratoxin A results in decreased expression of PCK1 mRNA; ochratoxin A results in decreased expression of PCK1 protein

NCBI chr17:57,930,507...57,936,523
Ensembl chr17:57,930,432...57,936,522

G

proliferating cell nuclear antigen

decreases expression

ochratoxin A results in decreased expression of PCNA protein

NCBI chr17:14,137,746...14,142,584
Ensembl chr17:14,136,886...14,142,744

G

peptidylprolyl isomerase A

increases expression

ochratoxin A results in increased expression of PPIA mRNA

NCBI chr18:50,563,130...50,566,857

G

peroxiredoxin 1

decreases expression

ochratoxin A results in decreased expression of PRDX1 mRNA

NCBI chr 6:165,847,390...165,859,918
Ensembl chr 6:165,824,395...165,861,442

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of PTGS2 mRNA]; Taurine inhibits the reaction [ochratoxin A results in decreased expression of PTGS2 mRNA]

NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884

G

prothymosin alpha

decreases expression

ochratoxin A results in decreased expression of PTMA mRNA

NCBI chr15:132,353,763...132,361,442
Ensembl chr15:132,355,655...132,361,435

G

PYD and CARD domain containing

increases expression
multiple interactions

ochratoxin A results in increased expression of PYCARD protein
Acetylcysteine inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein]; Taurine inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein]

NCBI chr 3:17,305,921...17,307,521
Ensembl chr 3:17,306,099...17,307,786

G

RAD51 recombinase

increases expression

ochratoxin A results in increased expression of RAD51 protein

NCBI chr 1:130,592,414...130,640,326
Ensembl chr 1:130,586,665...130,640,136

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]

NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469

G

replication protein A2

increases expression

ochratoxin A results in increased expression of RPA2 protein

NCBI chr 6:85,032,604...85,045,899
Ensembl chr 6:85,031,582...85,045,915

G

ribosomal protein S5

increases expression

ochratoxin A results in increased expression of RPS5 mRNA

NCBI chr 6:62,967,955...62,974,353
Ensembl chr 6:62,967,994...62,974,350

G

suppressor of cytokine signaling 3

increases expression
multiple interactions

ochratoxin A results in increased expression of SOCS3 mRNA; ochratoxin A results in increased expression of SOCS3 protein
Decitabine promotes the reaction [ochratoxin A results in increased expression of SOCS3 mRNA]; Decitabine promotes the reaction [ochratoxin A results in increased expression of SOCS3 protein]

NCBI chr12:3,643,832...3,647,015
Ensembl chr12:3,643,929...3,647,009

G

superoxide dismutase 1

decreases activity

ochratoxin A results in decreased activity of SOD1 protein

NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729

G

secreted phosphoprotein 1

multiple interactions
increases expression

fumonisin B1 promotes the reaction [ochratoxin A results in increased expression of SPP1 mRNA]; ochratoxin A promotes the reaction [fumonisin B1 results in increased expression of SPP1 mRNA]

NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340

G

sequestosome 1

multiple interactions
decreases expression

Chloroquine inhibits the reaction [ochratoxin A results in decreased expression of SQSTM1 protein]

NCBI chr 2:78,752,768...78,763,998
Ensembl chr 2:78,752,771...78,763,938

G

signal transducer and activator of transcription 3

multiple interactions
increases phosphorylation

Decitabine inhibits the reaction [ochratoxin A results in increased phosphorylation of STAT3 protein]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]; STAT3 protein affects the reaction [ochratoxin A results in increased expression of H2AX protein]

NCBI chr12:20,407,316...20,471,091
Ensembl chr12:20,407,233...20,472,992

G

small ubiquitin like modifier 1

decreases expression

ochratoxin A results in decreased expression of SUMO1 mRNA

NCBI chr15:105,820,237...105,850,099
Ensembl chr15:105,818,858...105,850,233

G

transforming growth factor beta 1

increases expression
multiple interactions

ochratoxin A results in increased expression of TGFB1 mRNA
NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; sulforaphane inhibits the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]

NCBI chr 6:49,332,169...49,348,642
Ensembl chr 6:49,332,173...49,349,046

G

TIMP metallopeptidase inhibitor 2

increases expression

ochratoxin A results in increased expression of TIMP2 mRNA

NCBI chr12:3,254,794...3,300,835
Ensembl chr12:3,254,493...3,300,834

G

tight junction protein 1

affects localization

ochratoxin A affects the localization of TJP1 protein

NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836

G

toll like receptor 4

multiple interactions

ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TLR4 protein]; TLR4 protein affects the reaction [ochratoxin A affects the expression of BCL2 mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]

NCBI chr 1:258,044,610...258,054,641
Ensembl chr 1:258,044,610...258,058,970

G

tumor necrosis factor

multiple interactions
increases secretion

ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]
ochratoxin A results in increased secretion of TNF protein

PMID:28528741 PMID:28699257

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416

G

tumor protein p53

multiple interactions
increases expression

NFE2L2 protein affects the reaction [ochratoxin A results in increased expression of TP53 protein]

PMID:28710020 PMID:32454083

NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818

G

XPA, DNA damage recognition and repair factor

decreases expression

ochratoxin A results in decreased expression of XPA mRNA

NCBI chr 1:239,532,331...239,568,589
Ensembl chr 1:239,532,272...239,568,570

G

X-ray repair cross complementing 1

increases expression

ochratoxin A results in increased expression of XRCC1 protein

NCBI chr 6:50,403,691...50,425,730
Ensembl chr 6:50,403,689...50,425,729

ochratoxin B

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

NFE2 like bZIP transcription factor 2

decreases activity

ochratoxin B results in decreased activity of NFE2L2 protein

NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183

orlistat

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

pancreatic lipase

decreases activity

Orlistat results in decreased activity of PNLIP protein

NCBI chr14:126,771,920...126,789,097
Ensembl chr14:126,772,911...126,790,001

phosphatidylcholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 4

increases export
multiple interactions

ABCB4 protein results in increased export of Phosphatidylcholines
Itraconazole inhibits the reaction [ABCB4 protein results in increased export of Phosphatidylcholines]; Verapamil inhibits the reaction [ABCB4 protein results in increased export of Phosphatidylcholines]

NCBI chr 9:93,171,371...93,262,124

G

protein disulfide isomerase family A member 3

increases hydrolysis

PDIA3 protein results in increased hydrolysis of Phosphatidylcholines

NCBI chr 1:127,786,174...127,814,096
Ensembl chr 1:127,785,772...127,814,196

potassium atom

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily D member 2

increases transport

KCND2 protein results in increased transport of Potassium

NCBI chr18:26,139,457...26,624,210
Ensembl chr18:26,139,457...26,623,233

G

opioid receptor mu 1

multiple interactions

Enkephalin, Ala(2)-MePhe(4)-Gly(5)- inhibits the reaction [OPRM1 protein affects the reaction [Potassium results in increased abundance of Catecholamines]]; Enkephalin, Ala(2)-MePhe(4)-Gly(5)- inhibits the reaction [OPRM1 protein affects the reaction [Potassium results in increased transport of Barium]]; OPRM1 protein affects the reaction [Potassium results in increased abundance of Catecholamines]; OPRM1 protein affects the reaction [Potassium results in increased transport of Barium]

NCBI chr 1:12,634,125...12,702,295
Ensembl chr 1:12,528,672...12,702,443

potassium chromate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glyceraldehyde-3-phosphate dehydrogenase

decreases activity

potassium chromate(VI) results in decreased activity of GAPDH protein

NCBI chr 5:64,129,678...64,135,194
Ensembl chr 5:64,129,679...64,133,991

potassium hexacyanoferrate(3-)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nitric oxide synthase 3

decreases activity

potassium ferricyanide results in decreased activity of NOS3 protein

NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943

ritonavir

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nitric oxide synthase 3

multiple interactions
decreases expression

Masoprocol inhibits the reaction [Ritonavir results in decreased expression of NOS3 mRNA]; Masoprocol inhibits the reaction [Ritonavir results in decreased expression of NOS3 protein]; Ritonavir results in decreased expression of and results in decreased activity of NOS3 protein
Ritonavir results in decreased expression of NOS3 mRNA; Ritonavir results in decreased expression of NOS3 protein

PMID:15681703 PMID:16123675 PMID:22037733

NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943

S-adenosyl-L-methioninate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catechol-O-methyltransferase

multiple interactions

[S-Adenosylmethionine analog co-treated with COMT protein] results in increased methylation of catechol

NCBI chr14:51,384,729...51,403,997
Ensembl chr14:51,385,738...51,403,998

S-adenosyl-L-methionine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catechol-O-methyltransferase

multiple interactions

[S-Adenosylmethionine analog co-treated with COMT protein] results in increased methylation of catechol

NCBI chr14:51,384,729...51,403,997
Ensembl chr14:51,385,738...51,403,998

salubrinal

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

eukaryotic translation initiation factor 2A

increases phosphorylation

salubrinal results in increased phosphorylation of EIF2A protein

NCBI chr13:90,761,453...90,804,274
Ensembl chr13:90,761,465...90,804,274

saquinavir

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nitric oxide synthase 3

decreases expression

Saquinavir results in decreased expression of NOS3 mRNA

NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943

sinefungin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catechol-O-methyltransferase

decreases activity

sinefungin results in decreased activity of COMT protein

NCBI chr14:51,384,729...51,403,997
Ensembl chr14:51,385,738...51,403,998

sodium arsenite

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of CLDN1 mRNA]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of CLDN1 protein]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of OCLN mRNA]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of OCLN protein]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of TJP1 mRNA]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of TJP1 protein]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ARNT mRNA]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ATG5 mRNA]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ATG5 protein]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of BECN1 mRNA]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of CYP1A1 mRNA]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of MAP1LC3A mRNA]]; sodium arsenite promotes the reaction [deoxynivalenol affects the localization of AHR protein]; sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of AHR mRNA]

NCBI chr 9:86,511,866...86,555,950
Ensembl chr 9:86,511,369...86,555,943

G

AKT serine/threonine kinase 1

increases degradation
multiple interactions
decreases expression

sodium arsenite results in increased degradation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in increased degradation of AKT1 protein]; sodium arsenite results in decreased expression of and results in increased phosphorylation of AKT1 protein; Wortmannin inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein]
sodium arsenite results in decreased expression of AKT1 protein

PMID:12760830 PMID:16239170

G

aryl hydrocarbon receptor nuclear translocator

multiple interactions

AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ARNT mRNA]]; sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ARNT mRNA]

NCBI chr 4:98,333,431...98,390,012
Ensembl chr 4:98,333,459...98,389,457

G

autophagy related 5

multiple interactions

6-formylindolo(3,2-b)carbazole promotes the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ATG5 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ATG5 protein]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ATG5 mRNA]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ATG5 protein]]; sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ATG5 mRNA]; sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ATG5 protein]

NCBI chr 1:72,343,950...72,520,402
Ensembl chr 1:72,270,799...72,520,396

G

beclin 1

multiple interactions

6-formylindolo(3,2-b)carbazole promotes the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of BECN1 mRNA]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of BECN1 mRNA]]; sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of BECN1 mRNA]

NCBI chr12:20,041,914...20,054,249
Ensembl chr12:20,041,956...20,054,373

G

claudin 1

multiple interactions

6-formylindolo(3,2-b)carbazole inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of CLDN1 mRNA]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of CLDN1 protein]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of CLDN1 mRNA]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of CLDN1 protein]]; sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of CLDN1 mRNA]; sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of CLDN1 protein]

NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657

G

cytochrome P450 family 1 subfamily A member 1

multiple interactions

AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of CYP1A1 mRNA]]; sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of CYP1A1 mRNA]

NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775

G

hypoxia inducible factor 1 subunit alpha

multiple interactions
increases expression

bisindolylmaleimide I inhibits the reaction [sodium arsenite results in increased expression of HIF1A mRNA]; Go 6976 inhibits the reaction [sodium arsenite results in increased expression of HIF1A mRNA]
sodium arsenite results in increased expression of HIF1A mRNA; sodium arsenite results in increased expression of HIF1A protein

NCBI chr 1:190,625,436...190,673,926
Ensembl chr 1:190,625,244...190,674,845

G

microtubule associated protein 1 light chain 3 alpha

multiple interactions

6-formylindolo(3,2-b)carbazole promotes the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of MAP1LC3A mRNA]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of MAP1LC3A mRNA]]; sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of MAP1LC3A mRNA]

NCBI chr17:37,957,830...37,959,505
Ensembl chr17:37,957,507...37,959,505

G

mitogen-activated protein kinase 6

increases expression

sodium arsenite results in increased expression of MAPK6 protein

NCBI chr 1:119,725,026...119,770,988
Ensembl chr 1:119,725,029...119,771,312

G

nitric oxide synthase 3

multiple interactions
increases degradation
decreases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [sodium arsenite results in increased phosphorylation of NOS3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sodium arsenite results in increased degradation of NOS3 protein]; sodium arsenite results in increased phosphorylation of and results in decreased activity of NOS3 protein; Wortmannin inhibits the reaction [sodium arsenite results in increased phosphorylation of NOS3 protein]
sodium arsenite results in decreased expression of NOS3 protein

NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943

G

occludin

multiple interactions

6-formylindolo(3,2-b)carbazole inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of OCLN mRNA]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of OCLN mRNA]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of OCLN protein]]; sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of OCLN mRNA]; sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of OCLN protein]

NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033

G

protein kinase cAMP-activated catalytic subunit alpha

decreases expression

sodium arsenite results in decreased expression of PRKACA protein

NCBI chr 2:65,074,876...65,095,564
Ensembl chr 2:65,074,870...65,095,551

G

protein kinase C delta

increases phosphorylation

sodium arsenite results in increased phosphorylation of PRKCD protein

NCBI chr13:35,290,835...35,323,245
Ensembl chr13:35,290,610...35,323,356

G

ribosomal protein S6 kinase A1

decreases expression

sodium arsenite results in decreased expression of RPS6KA1 protein

NCBI chr 6:83,905,124...83,947,189
Ensembl chr 6:83,905,077...83,950,963

G

superoxide dismutase 1

multiple interactions
increases activity

[sodium arsenite results in increased activity of SOD1 protein] which results in increased abundance of Hydrogen Peroxide

NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729

G

tight junction protein 1

multiple interactions

6-formylindolo(3,2-b)carbazole inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of TJP1 mRNA]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of TJP1 protein]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of TJP1 mRNA]]; AHR protein affects the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of TJP1 protein]]; sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of TJP1 mRNA]; sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of TJP1 protein]

NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836

G

tumor protein p53

increases expression

sodium arsenite results in increased expression of TP53

NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818

G

vascular endothelial growth factor A

increases expression
multiple interactions

sodium arsenite results in increased expression of VEGFA mRNA
bisindolylmaleimide I inhibits the reaction [sodium arsenite results in increased expression of VEGFA mRNA]; R 59949 promotes the reaction [sodium arsenite results in increased expression of VEGFA mRNA]; sodium arsenite results in increased expression of and results in increased secretion of VEGFA protein

NCBI chr 7:38,746,393...38,762,282
Ensembl chr 7:38,746,052...38,761,366

sodium atom

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

transient receptor potential cation channel subfamily V member 1

affects response to substance
affects activity
multiple interactions

TRPV1 protein affects the susceptibility to Sodium
Sodium affects the activity of TRPV1 protein
capsazepine inhibits the reaction [Sodium affects the reaction [TRPV1 protein results in increased abundance of Calcium]]; iodoresiniferatoxin inhibits the reaction [Sodium affects the reaction [TRPV1 protein results in increased abundance of Calcium]]; Ruthenium Red inhibits the reaction [Sodium affects the reaction [TRPV1 protein results in increased abundance of Calcium]]; Sodium affects the reaction [TRPV1 protein results in increased abundance of Calcium]

NCBI chr12:49,676,536...49,709,634
Ensembl chr12:49,677,291...49,713,977

sodium benzoate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

D-amino acid oxidase

decreases activity

Sodium Benzoate results in decreased activity of DAO protein

NCBI chr14:41,931,549...41,950,628
Ensembl chr14:41,931,541...41,950,633

sodium borohydride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

chemokine (C-C motif) ligand 2

multiple interactions

sodium borohydride inhibits the reaction [[2,2'-azobis(2-amidinopropane) results in increased oxidation of Docosahexaenoic Acids] inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]]

NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026

sodium dichromate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

decreases expression

sodium bichromate results in decreased expression of AKT1 protein

sodium disulfite

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-X-C motif chemokine ligand 8

multiple interactions

sodium metabisulfite inhibits the reaction [deoxynivalenol results in increased expression of CXCL8 mRNA]

NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861

G

interleukin 6

multiple interactions

sodium metabisulfite inhibits the reaction [deoxynivalenol results in increased expression of IL6 mRNA]

NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263

sodium hydrogencarbonate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glyceraldehyde-3-phosphate dehydrogenase

multiple interactions

[Sodium Bicarbonate co-treated with Calcium Chloride] results in increased activity of GAPDH protein

NCBI chr 5:64,129,678...64,135,194
Ensembl chr 5:64,129,679...64,133,991

sodium iodide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 5 member 5

multiple interactions
increases uptake

sodium perchlorate inhibits the reaction [SLC5A5 protein alternative form results in increased uptake of Sodium Iodide]; sodium perchlorate inhibits the reaction [SLC5A5 protein results in increased uptake of Sodium Iodide]
SLC5A5 protein alternative form results in increased uptake of Sodium Iodide; SLC5A5 protein results in increased uptake of Sodium Iodide

NCBI chr 2:59,869,157...59,885,086
Ensembl chr 2:59,869,155...59,885,266

sodium perchlorate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 5 member 5

multiple interactions

sodium perchlorate inhibits the reaction [SLC5A5 protein alternative form results in increased uptake of Sodium Iodide]; sodium perchlorate inhibits the reaction [SLC5A5 protein results in increased uptake of Sodium Iodide]

NCBI chr 2:59,869,157...59,885,086
Ensembl chr 2:59,869,155...59,885,266

G

thyroid peroxidase

decreases activity

sodium perchlorate results in decreased activity of TPO protein

NCBI chr 3:132,384,677...132,409,750
Ensembl chr 3:132,384,583...132,409,208

tacrolimus hydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

increases activity

Tacrolimus results in increased activity of CASP3 protein

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

taurine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 1, apoptosis-related cysteine peptidase

multiple interactions

Taurine inhibits the reaction [ochratoxin A results in increased expression of and results in increased cleavage of CASP1 protein]

NCBI chr 9:35,188,066...35,199,364
Ensembl chr 9:35,186,420...35,200,328

G

catalase

multiple interactions

Taurine inhibits the reaction [ochratoxin A results in decreased expression of CAT mRNA]

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

glutathione peroxidase 1

multiple interactions

Taurine inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA]

NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433

G

glutathione peroxidase 4

multiple interactions

Taurine inhibits the reaction [ochratoxin A results in decreased expression of GPX4 mRNA]

NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,931

G

gasdermin D

multiple interactions

Taurine inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]

NCBI chr 4:995,753...1,001,964
Ensembl chr 4:995,763...1,000,271

G

interleukin-1 beta-like

multiple interactions

Taurine inhibits the reaction [ochratoxin A results in increased expression of IL1B protein]

G

NLR family pyrin domain containing 3

multiple interactions

Taurine inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein]

NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228

G

nitric oxide synthase 2

multiple interactions

Taurine inhibits the reaction [ochratoxin A results in decreased expression of INOS mRNA]

NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146

G

prostaglandin-endoperoxide synthase 2

multiple interactions

Taurine inhibits the reaction [ochratoxin A results in decreased expression of PTGS2 mRNA]

NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884

G

PYD and CARD domain containing

multiple interactions

Taurine inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein]

NCBI chr 3:17,305,921...17,307,521
Ensembl chr 3:17,306,099...17,307,786

taurocholic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

increases transport

ABCB11 protein results in increased transport of Taurocholic Acid

NCBI chr15:75,402,296...75,487,092
Ensembl chr15:75,402,396...75,486,403

G

solute carrier organic anion transporter family member 1A2

increases uptake
multiple interactions

SLCO1A2 protein results in increased uptake of Taurocholic Acid
Amoxicillin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; cefquinome inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Clarithromycin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Doxycycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; epigallocatechin gallate inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Erythromycin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Oxytetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Penicillins inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Tetracycline inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; tilmicosin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]; Tylosin inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]

NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730

tauroursodeoxycholic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

activating transcription factor 4

multiple interactions

ursodoxicoltaurine inhibits the reaction [Cadmium results in increased expression of ATF4 mRNA]

NCBI chr 5:8,742,964...8,745,752
Ensembl chr 5:8,742,967...8,745,368

G

activating transcription factor 6

multiple interactions

ursodoxicoltaurine inhibits the reaction [Cadmium results in increased expression of ATF6 mRNA]

NCBI chr 4:88,591,279...88,806,156
Ensembl chr 4:88,591,288...88,805,304

G

catalase

multiple interactions

ursodoxicoltaurine inhibits the reaction [Cadmium results in increased expression of CAT mRNA]

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

DNA damage inducible transcript 3

multiple interactions

ursodoxicoltaurine inhibits the reaction [Cadmium results in increased expression of DDIT3 mRNA]

NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829

G

heat shock protein family A (Hsp70) member 5

multiple interactions

ursodoxicoltaurine inhibits the reaction [Cadmium results in increased expression of HSPA5 mRNA]

NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894

G

prostaglandin-endoperoxide synthase 1

multiple interactions

ursodoxicoltaurine inhibits the reaction [Cadmium results in decreased expression of PTGS1 mRNA]

NCBI chr 1:262,456,106...262,482,159
Ensembl chr 1:262,456,155...262,483,035

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ursodoxicoltaurine inhibits the reaction [Cadmium results in decreased expression of PTGS2 mRNA]

NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884

G

pentraxin 3

multiple interactions

ursodoxicoltaurine inhibits the reaction [Cadmium results in decreased expression of PTX3 mRNA]

NCBI chr13:97,273,594...97,279,570
Ensembl chr13:97,273,594...97,279,569

G

superoxide dismutase 1

multiple interactions

ursodoxicoltaurine inhibits the reaction [Cadmium results in increased expression of SOD1 mRNA]

NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729

G

superoxide dismutase 2

multiple interactions

ursodoxicoltaurine affects the reaction [Cadmium results in increased expression of SOD2 mRNA]

NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560

G

TNF alpha induced protein 6

multiple interactions

[ursodoxicoltaurine co-treated with Cadmium] results in increased expression of TNFAIP6 mRNA; ursodoxicoltaurine inhibits the reaction [Cadmium results in decreased expression of TNFAIP6 mRNA]

NCBI chr15:862,013...881,352
Ensembl chr15:862,015...881,461

G

X-box binding protein 1

multiple interactions

ursodoxicoltaurine inhibits the reaction [Cadmium results in increased splicing of XBP1 mRNA]

NCBI chr14:46,011,239...46,016,526
Ensembl chr14:46,008,377...46,016,526

tetraethylammonium

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 2

increases uptake
multiple interactions

SLC22A2 protein results in increased uptake of Tetraethylammonium
Quercetin inhibits the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium]; Rutin inhibits the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium]

NCBI chr 1:7,289,278...7,323,418
Ensembl chr 1:7,289,831...7,323,146

thymol sulfate(1-)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ryanodine receptor 1

increases activity

Thymol results in increased activity of RYR1 protein

NCBI chr 6:47,339,759...47,458,457
Ensembl chr 6:47,343,768...47,458,458

urea

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

growth hormone 1

multiple interactions

GH1 protein inhibits the reaction [Lipopolysaccharides results in increased abundance of Urea]

NCBI chr12:15,064,965...15,066,698
Ensembl chr12:15,064,909...15,066,696

water

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aquaporin 1 (Colton blood group)

increases transport
multiple interactions

AQP1 protein results in increased transport of Water
Mercuric Chloride inhibits the reaction [AQP1 protein results in increased transport of Water]

NCBI chr18:42,063,482...42,076,741
Ensembl chr18:42,063,485...42,076,746

zileuton

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arachidonate 5-lipoxygenase

decreases activity

zileuton results in decreased activity of ALOX5 protein

NCBI chr14:90,859,209...90,907,084
Ensembl chr14:90,859,016...90,907,094

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	5177
role	5144
biological role	5144
biochemical role	5066
metabolite	5054
eukaryotic metabolite	5036
fungal metabolite	4709
Saccharomyces cerevisiae metabolite	314
(1->3)-beta-D-glucan +	0
(1->6)-beta-D-glucan	0
(1s,4s)-prephenate(2-)	0
(2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl diphosphate(3-)	0
(2E)-2-ethylidene-4-hydroxy-5-methyl-3(2H)-furanone	0
(2E)-3-(methoxycarbonyl)pent-2-enedioate(2-)	0
(2R,3R)-2,3-dihydroxy-3-methylpentanoate	0
(2R,3S)-3-isopropylmalate(2-)	0
(2S)-2-isopropyl-3-oxosuccinate(2-)	0
(2S,3R)-3-hydroxybutane-1,2,3-tricarboxylate	0
(4R)-N-(2,3-dihydroxytetracosanoyl)-4-hydroxysphinganine +	0
(5S,6S)-dihydroxy-(7E,9E,11Z,14Z)-icosatetraenoic acid	0
(6R)-5,10-methenyltetrahydrofolate +	0
(6S)-5-formyltetrahydrofolate(2-)	0
(6S)-5-methyltetrahydrofolate(2-) +	0
(N(omega)-L-arginino)succinate(1-)	0
(R)-2,3-dihydroxy-3-methylbutanoate	0
(R)-4'-phosphopantothenic acid	0
(R)-5-diphosphonatomevalonate(4-)	0
(R)-5-phosphonatomevalonate(3-)	0
(R)-S-lactoylglutathionate(1-)	0
(R)-S-lactoylglutathione	0
(R)-acetoin	0
(R)-carnitine +	1
(R)-lactate +	0
(R)-mevalonate +	0
(R)-pantoate	0
(R)-pantolactone	0
(R)-pantothenate	0
(R)-phenylacetylcarbinol +	0
(R,R)-butane-2,3-diol	0
(S)-2,3-epoxysqualene	0
(S)-2-acetyl-2-hydroxybutanoate	0
(S)-3-hydroxydecanoyl-CoA	0
(S)-3-hydroxyhexacosanoyl-CoA	0
(S)-3-hydroxylauroyl-CoA	0
(S)-3-hydroxypalmitoyl-CoA	0
(S)-3-hydroxytetradecanoyl-CoA	0
(S)-3-methyl-2-oxovalerate	0
(S)-dihydroorotate	0
(S)-dihydroorotic acid	0
(S)-lactaldehyde	0
(S)-lactate +	0
(S)-malate(2-) +	0
1-(2-carboxylatophenylamino)-1-deoxy-D-ribulose 5-phosphate(3-)	0
1-(5-phospho-D-ribosyl)-ATP(6-) +	0
1-(5-phospho-beta-D-ribosyl)-5-[(5-phospho-beta-D-ribosylamino)methylideneamino]imidazole-4-carboxamide(4-)	0
1-(5-phosphonato-beta-D-ribosyl)-5'-AMP(4-)	0
1-(sn-glycero-3-O-phosphonato)-1D-myo-inositol	0
1-C-(indol-3-yl)glycerol 3-phosphate(2-)	0
1-methylnicotinamide +	0
1-pyrroline-3-hydroxy-5-carboxylate	0
1-pyrroline-5-carboxylate +	0
10-formyltetrahydrofolate(2-) +	0
14-demethyllanosterol +	0
1D-myo-inositol 1,3,4,5-tetrakisphosphate(8-)	0
1D-myo-inositol 1,4,5,6-tetrakisphosphate(8-)	0
1D-myo-inositol 1,4,5-trisphosphate(6-)	0
1D-myo-inositol 1-phosphate(2-)	0
1D-myo-inositol 3-phosphate(2-)	0
2',3'-cyclic AMP(1-)	0
2'-deoxyadenosine +	0
2'-deoxycytidine +	0
2'-deoxycytosine 5'-monophosphate(2-) +	0
2'-deoxyguanosine +	0
2'-deoxyguanosine 5'-monophosphate(2-) +	0
2'-deoxyinosine	0
2'-deoxyinosine-5'-diphosphate	0
2'-deoxyuridine +	0
2,3-bisphosphonato-D-glycerate(5-)	0
2,5-diamino-4-hydroxy-6-(5-phosphonatoribosylamino)pyrimidine(3-)	0
2,5-diamino-6-(5-phosphono)ribitylamino-4(3H)-pyrimidinone	0
2-(3-amino-3-carboxypropyl)-L-histidine +	0
2-[3-carboxylato-3-(methylammonio)propyl]-L-histidine dizwitterion +	0
2-acetamido-5-oxopentanoate	0
2-acetyllactate	0
2-amino-3-(3-oxoprop-1-enyl)but-2-enedioate +	0
2-amino-6-(hydroxymethyl)-7,8-dihydropteridin-4-ol	0
2-dehydropantoate	0
2-deoxy-D-ribofuranose	0
2-deoxy-D-ribose +	0
2-deoxy-D-ribose 5-phosphate(2-)	0
2-ethyl-4-hydroxy-5-methyl-3(2H)-furanone	0
2-formamido-N(1)-(5-O-phosphonato-D-ribosyl)acetamidine +	0
2-furoate	0
2-furoic acid +	0
2-hexaprenyl-6-methoxy-1,4-benzoquinone	0
2-hexaprenyl-6-methoxy-3-methyl-1,4-benzoquinone	0
2-hexaprenyl-6-methoxyphenol	0
2-hydroxy-3-oxobutyl phosphate +	0
2-hydroxyhexadecanal +	0
2-isopropylmalate(2-) +	0
2-isopropylmaleate(2-)	0
2-methylbutan-1-ol +	0
2-methylbutanal +	0
2-methylbutyl acetate	0
2-methylcitrate(3-) +	0
2-oxoadipate(2-)	0
2-oxobutanoate	0
2-oxoglutarate(2-)	0
2-phenylethanol +	2
2-phospho-D-glyceric acid	0
2-phosphonato-D-glycerate(3-)	0
2-trans,6-trans,10-trans-geranylgeranyl diphosphate(3-)	0
2-trans,6-trans-farnesyl diphosphate(3-)	0
3',5'-cyclic AMP(1-)	0
3',5'-cyclic CMP(1-)	0
3',5'-cyclic GMP +	3
3',5'-cyclic GMP(1-) +	0
3',5'-cyclic IMP	0
3',5'-cyclic dAMP	0
3'-dephospho-CoA(2-)	0
3'-phosphonato-5'-adenylyl sulfate(4-)	0
3-(4-hydroxyphenyl)pyruvate	0
3-(imidazol-4-yl)-2-oxopropyl phosphate(2-)	0
3-(indol-3-yl)pyruvate	0
3-(indol-3-yl)pyruvic acid	0
3-amino-4-iodopyridine	0
3-ammoniopropanal	0
3-dehydro-4-methylzymosterol +	0
3-dehydroquinate	0
3-dehydroshikimate	0
3-dehydrosphinganinium(1+) +	0
3-demethylubiquinone-6	0
3-hexaprenyl-4,5-dihydroxybenzoate	0
3-hexaprenyl-4-hydroxy-5-methoxybenzoate	0
3-hexaprenyl-4-hydroxybenzoic acid	0
3-hydroxy-2-isopropyl-4-methoxy-4-oxobutanoate	0
3-hydroxy-3-methylglutaryl-CoA +	0
3-hydroxy-L-kynurenine	0
3-hydroxyanthranilate	0
3-hydroxydocosanoyl-CoA +	0
3-hydroxyicosanoyl-CoA +	0
3-hydroxyoctadecanoyl-CoA +	0
3-hydroxytetracosanoyl-CoA	0
3-mercaptohexanol +	0
3-mercaptohexyl acetate	0
3-methyl-2-oxobutanoate	0
3-methyl-2-oxobutanoic acid	0
3-methylbutanal	0
3-methylthiopropanol +	0
3-oxodecanoyl-CoA	0
3-oxodocosanoyl-CoA	0
3-oxohexacosanoyl-CoA	0
3-oxoicosanoyl-CoA	0
3-oxolauroyl-CoA	0
3-oxooctadecanoyl-CoA	0
3-oxopalmitoyl-CoA(4-)	0
3-oxotetracosanoyl-CoA	0
3-oxotetradecanoyl-CoA	0
3-phosphonato-D-glyceroyl phosphate(4-)	0
3-phosphonatooxypyruvate(3-)	0
3-phosphonatoshikimate(3-)	0
4,4-dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol	0
4,5-bis(diphospho)-1D-myo-inositol tetrakisphosphate	0
4-(phosphonatooxy)-L-threonine(2-)	0
4-amino-2-methyl-5-diphosphonatooxymethylpyrimidine(3-)	0
4-amino-2-methyl-5-phosphonatooxymethylpyrimidine(2-)	0
4-amino-4-deoxychorismate(2-)	0
4-amino-5-hydroxymethyl-2-methylpyrimidine	0
4-aminobenzoate +	0
4-ammoniobutanal	0
4-diphospho-1D-myo-inositol pentakisphosphate	0
4-formylzymosterol +	0
4-guanidiniumylbutanamide(1+)	0
4-guanidinobutanoic acid	0
4-hydroxy-2-oxoglutarate(2-) +	0
4-hydroxy-L-threonine	0
4-hydroxybenzoate +	0
4-hydroxybenzoyl-CoA(4-)	0
4-hydroxymethylzymosterol +	0
4-mercapto-4-methylpentan-2-one	0
4-methyl-2-oxopentanoate	0
4-methyl-5-(2-phosphonatooxyethyl)thiazole(2-)	0
4-methylthio-2-oxobutanoate +	0
4-oxobutanoate	0
4-phospho-L-aspartate	0
4alpha-methylzymosterol +	0
4beta-methylzymosterol-4alpha-carboxylic acid	0
5'-S-methyl-5'-thioadenosine	0
5'-adenylyl sulfate(2-)	0
5'-xanthylate(2-)	0
5,10-methylenetetrahydrofolate(2-) +	0
5,6,7,8-tetrahydrofolic acid +	0
5,6,7,8-tetrahydrofolyl-L-glutamic acid	0
5,6-bis(diphospho)-1D-myo-inositol tetrakisphosphate	0
5-(2-hydroxyethyl)-4-methylthiazole	0
5-(methylsulfanyl)-2,3-dioxopentyl phosphate(2-)	0
5-O-(1-carboxylatovinyl)-3-phosphonatoshikimate	0
5-O-phosphonato-alpha-D-ribofuranosyl diphosphate(5-)	0
5-[(5-phospho-1-deoxy-D-ribulos-1-ylimino)methylamino]-1-(5-phospho-beta-D-ribosyl)imidazole-4-carboxamide(4-)	0
5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide(2-) +	0
5-amino-1-(5-phosphonato-D-ribosyl)imidazol-3-ium	0
5-amino-1-(5-phosphonato-D-ribosyl)imidazole-4-carboxylate	0
5-amino-6-(5-phosphoribitylamino)uracil(2-)	0
5-amino-6-(D-ribitylamino)uracil	0
5-aminolevulinic acid +	0
5-diphospho-1D-myo-inositol pentakisphosphate(13-)	0
5-formamido-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide(2-)	0
5-hydroxyfuran-2-carboxylic acid	0
5-methyltetrahydropteroyltri-L-glutamate(4-)	0
5-phospho-beta-D-ribosylaminium(1-)	0
6,7-dimethyl-8-(1-D-ribityl)lumazine(1-)	0
6-(N-acetyl-alpha-D-glucosaminyl)-1-phosphatidyl-1D-myo-inositol(1-) +	0
6-(alpha-D-glucosaminyl)-1-phosphatidyl-1D-myo-inositol +	0
6-(alpha-D-glucosaminyl)-O-acyl-1-phosphatidyl-1D-myo-inositol	0
6-O-[alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl]-O-acyl-1-phosphatidyl-1D-myo-inositol	0
6-O-\{2-O-[(2-aminoethyl)phosphoryl]-alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl\}-O-acyl-1-phosphatidyl-1D-myo-inositol	0
6-O-\{alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->6)-2-O-[(2-aminoethyl)phosphoryl]-alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl\}-O-acyl-1-phosphatidyl-1D-myo-inositol	0
6-O-\{alpha-D-mannosyl-(1->6)-2-O-[(2-aminoethyl)phosphoryl]-alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl\}-O-acyl-1-phosphatidyl-1D-myo-inositol	0
6-O-phosphonato-D-glucono-1,5-lactone(2-)	0
6-[6-(2-aminoethylphosphoryl)-alpha-mannosyl-(1->6)-2-(2-aminoethylphosphoryl)-alpha-mannosyl-(1->6)-alpha-2-(2-aminoethylphosphoryl)mannosyl-(1->4)-alpha-glucosaminyl]-O-acyl-1-phosphatidyl-1D-myo-inositol +	0
6-diphospho-1D-myo-inositol pentakisphosphate	0
7,8-diaminononanoate	0
7,8-dihydroneopterin +	0
7,8-dihydroneopterin 3'-phosphate(2-)	0
7,8-dihydroneopterin 3'-triphosphate(4-)	0
7,8-dihydropteroate +	0
7-phospho-2-dehydro-3-deoxy-D-arabino-heptonate	0
8-amino-7-oxononanoic acid	0
9H-xanthine +	0
A-factor	0
ADP-D-ribose(2-) +	0
AICA ribonucleotide	0
Ala-tRNA(Ala)	0
Arg-tRNA(Arg)	0
Asn-tRNA(Asn)	0
Asp-tRNA(Asp)	0
CDP(3-) +	0
CDP-choline	0
CDP-ethanolamine(1-)	0
CTP(4-) +	0
Cys-tRNA(Cys)	0
D-arabinono-1,4-lactone	0
D-arabinose +	0
D-erythro-1-(imidazol-4-yl)glycerol 3-phosphate(2-)	0
D-erythrose 4-phosphate(2-)	0
D-fructose +	0
D-fructose 6-phosphate(2-)	0
D-galactose +	0
D-glucitol +	0
D-glucopyranose +	13
D-glyceraldehyde +	0
D-histidinate(1-)	0
D-histidinate(2-)	0
D-histidine +	0
D-histidinium(1+) +	0
D-histidinium(2+)	0
D-isoleucinate	0
D-isoleucine +	0
D-isoleucinium	0
D-leucinate	0
D-leucine +	0
D-leucinium	0
D-mannose +	0
D-methioninate	0
D-methioninium	0
D-threoninate	0
D-threonine +	0
D-threoninium	0
D-xylulose +	0
D-xylulose 5-phosphate(2-) +	0
Delta(6)-trans,Delta(8)-cis-leukotriene B4	0
FAD(3-)	0
FADH2(2-) +	0
FMN(3-) +	0
FMNH2(2-)	0
GDP(3-) +	0
GDP-alpha-D-mannose(2-)	0
GDP-mannose +	0
GTP(3-) +	0
Gln-tRNA(Gln)	0
Glu-tRNA(Glu)	0
Gly-tRNA(Gly)	0
His-tRNA(His)	0
IDP(3-)	0
IMP(2-) +	0
ITP(4-)	0
Ile-tRNA(Ile)	0
Ins-1-P-6-Man-1-6-Ins-1-P-Cer(d18:0/2-OH-26:0)	0
Ins-1-P-6-Man-1-6-Ins-1-P-Cer(d18:0/26:0) +	0
Ins-1-P-6-Man-1-6-Ins-1-P-Cer(t18:0/2,3-OH-26:0)	0
Ins-1-P-6-Man-1-6-Ins-1-P-Cer(t18:0/26:0)	0
Ins-1-P-6-Man-beta1-3-Ins-1-P-Cer(t18:0/2-OH-26:0)	0
Ins-1-P-6-Man-beta1-6-Ins-1-P-Cer(d18:0/2-OH-24:0)	0
Ins-1-P-6-Man-beta1-6-Ins-1-P-Cer(d18:0/24:0)	0
Ins-1-P-6-Man-beta1-6-Ins-1-P-Cer(t18:0/2,3-OH-24:0)	0
Ins-1-P-6-Man-beta1-6-Ins-1-P-Cer(t18:0/2-OH-24:0)	0
Ins-1-P-6-Man-beta1-6-Ins-1-P-Cer(t18:0/24:0)	0
Ins-1-P-Cer(d18:0/2-OH-24:0) +	0
Ins-1-P-Cer(d18:0/2-OH-26:0) +	0
Ins-1-P-Cer(d18:0/24:0) +	0
Ins-1-P-Cer(d18:0/26:0) +	0
Ins-1-P-Cer(t18:0/2,3-OH-24:0) +	0
Ins-1-P-Cer(t18:0/2,3-OH-26:0) +	0
Ins-1-P-Cer(t18:0/2-OH-24:0) +	0
Ins-1-P-Cer(t18:0/2-OH-26:0) +	0
Ins-1-P-Cer(t18:0/24:0) +	0
Ins-1-P-Cer(t18:0/26:0) +	0
L-2-amino-3-oxobutanoic acid	0
L-2-aminoadipate(1-)	0
L-3-oxoalaninate	0
L-4-hydroxyglutamic semialdehyde	0
L-allothreonine	0
L-allysine +	0
L-arabinitol +	0
L-arabinose +	0
L-argininium(1+) +	0
L-asparagine +	1
L-aspartic 4-semialdehyde	0
L-citrulline +	0
L-cystathionine	0
L-cysteinylglycine +	0
L-cysteinylglycine zwitterion	0
L-cystine +	0
L-gamma-glutamyl phosphate(2-)	0
L-gamma-glutamyl-L-cysteinate(1-)	0
L-gamma-glutamyl-L-cysteine +	0
L-glucitol	0
L-glutamate(1-) +	9
L-glutamic 5-semialdehyde +	0
L-glutamine +	18
L-histidinate(1-)	0
L-histidinate(2-)	0
L-histidine +	0
L-histidinium(1+) +	0
L-histidinium(2+)	0
L-histidinol +	0
L-histidinol phosphate(1-)	0
L-histidinol(1+)	0
L-homoserine +	0
L-isoleucinate	0
L-isoleucine +	0
L-isoleucinium +	0
L-kynurenine +	0
L-leucinate +	0
L-leucine +	1
L-leucinium +	0
L-lysinate	0
L-lysine +	0
L-lysinium(1+) +	0
L-lysinium(2+) +	0
L-methioninate +	1
L-methioninium +	0
L-phenylalaninate +	0
L-phenylalanine +	80
L-phenylalaninium +	0
L-proline +	0
L-saccharopinate(1-)	0
L-saccharopine	0
L-serine +	0
L-sorbose +	0
L-threoninate	0
L-threonine +	0
L-threoninium +	0
L-tryptophan +	0
L-valine +	1
Leu-tRNA(Leu)	0
Lys-tRNA(Lys)	0
Man-1-6-Ins-1-P-Cer(d18:0/2-OH-26:0) +	0
Man-1-6-Ins-1-P-Cer(d18:0/26:0) +	0
Man-1-6-Ins-1-P-Cer(t18:0/2,3-OH-26:0) +	0
Man-1-6-Ins-1-P-Cer(t18:0/2-OH-26:0)	0
Man-1-6-Ins-1-P-Cer(t18:0/26:0) +	0
Man-beta1-6-Ins-1-P-Cer(d18:0/2-OH-24:0) +	0
Man-beta1-6-Ins-1-P-Cer(d18:0/24:0) +	0
Man-beta1-6-Ins-1-P-Cer(t18:0/2,3-OH-24:0) +	0
Man-beta1-6-Ins-1-P-Cer(t18:0/2-OH-24:0) +	0
Man-beta1-6-Ins-1-P-Cer(t18:0/24:0) +	0
Met-tRNA(Met)	0
N(1)-(5-phospho-D-ribosyl)glycinamide(1-) +	0
N(1)-acetylspermidinium(2+)	0
N(1)-acetylsperminium(3+)	0
N(2)-acetyl-L-ornithine	0
N(2)-formyl-N(1)-(5-phospho-D-ribosyl)glycinamide(2-) +	0
N(6)-(1,2-dicarboxylatoethyl)-AMP(4-)	0
N(pros)-methyl-L-histidine +	0
N,N'-diacetylchitobiosyldiphosphodolichol	0
N,N'-diformyldityrosine	0
N-(2,3-dihydroxyhexacosanoyl)-(4R)-hydroxysphinganine +	0
N-(2-hydroxyhexacosanoyl)sphinganine +	0
N-(2-hydroxyhexacosanyl)-(4R)-phytosphingosine	0
N-(2-hydroxytetracosanoyl)phytosphingosine +	0
N-(2-hydroxytetracosanoyl)sphinganine +	0
N-(5-phosphonato-beta-D-ribosyl)anthranilate	0
N-[(R)-4-phosphonatopantothenoyl]-L-cysteinate(3-)	0
N-acetyl-D-glucosamine 6-phosphate +	0
N-acetyl-D-glucosamine 6-phosphate(2-) +	0
N-acetyl-L-alanine +	0
N-acetyl-L-gamma-glutamyl phosphate(3-)	0
N-acetyl-L-glutamate(2-) +	0
N-acetyl-L-glutamic acid	0
N-acetyl-alpha-D-glucosamine 1-phosphate	0
N-acetylputrescinium	0
N-carbamoyl-L-aspartate(2-)	0
N-carbamoylaspartic acid +	0
N-formyl-L-kynurenine +	0
N-formyl-L-tyrosine	0
N-hexacosanoylphytosphingosine +	0
N-hexacosanoylsphinganine +	0
N-ribosylnicotinamide	0
N-tetracosanoylphytosphingosine +	0
N-tetracosanoylsphinganine +	0
NAD(1-) +	0
NADH(2-) +	0
NADP(3-)	0
NADPH(4-) +	0
NMN(-)	0
O-acetyl-L-carnitine	1
O-acetyl-L-homoserine	0
O-acetyl-L-serine +	0
O-phospho-L-serine +	0
O-phosphonato-L-homoserine(2-)	0
O-phosphonato-L-serine(2-) +	0
O-phosphonatoethanaminium(1-)	0
O-succinyl-L-homoserinate(1-)	0
O-succinyl-L-homoserine	0
P(1),P(4)-bis(5'-adenosyl) tetraphosphate(4-)	0
P(1),P(4)-bis(5'-guanosyl) tetraphosphate(4-)	0
P(1)-(5'-adenosyl),P(4)-(5'-guanosyl) tetraphosphate	0
Phe-tRNA(Phe)	0
Pro-tRNA(Pro)	0
S(8)-aminomethyldihydrolipoamide	0
S(8)-aminomethyldihydrolipoylprotein	0
S(8)-succinyldihydrolipoamide	0
S-adenosyl-4-methylthio-2-oxobutanoate	0
S-adenosyl-L-methionine +	1
S-adenosylmethioninaminium	0
S-formylglutathionate(1-)	0
S-formylglutathione	0
S-methyl-5-thio-D-ribulose 1-phosphate(2-)	0
S-methyl-5-thio-alpha-D-ribose 1-phosphate(2-)	0
S-methyl-L-methionine	0
SAICAR(4-)	0
Ser-tRNA(Ser)	0
Thr-tRNA(Thr)	0
Trp-tRNA(Trp)	0
Tyr-tRNA(Tyr)	0
UDP(3-)	0
UDP-D-galactose(2-) +	0
UDP-D-glucose(2-)	0
UDP-N-acetyl-alpha-D-glucosamine(2-)	0
UTP(4-) +	0
Val-tRNA(Val)	0
WHWLQLKPGQPMY	0
YIIKGLFWDPAC +	0
YIIKGVFWDPAC +	0
acetaldehyde +	1
acetate +	0
acetoacetyl-CoA(4-)	0
acetyl-CoA(4-)	0
acetyl-[acyl-carrier protein]	0
acyl-carrier protein +	0
adenine +	25
adenosine 2'-phosphate	0
adenosine 3',5'-bismonophosphate(4-)	0
aldehydo-D-galacturonate	0
aldehydo-D-xylose +	0
allantoate	0
allantoin +	0
alpha,alpha-trehalose +	0
alpha,alpha-trehalose 6-phosphate(2-)	0
alpha-D-galactose 1-phosphate(2-)	0
alpha-D-glucosamine 1-phosphate(1-)	0
alpha-D-glucosamine 6-phosphate	0
alpha-D-mannosyl-beta-D-mannosyldiacetylchitobiosyldiphosphodolichol	0
alpha-D-ribose 1-phosphate(2-)	0
ammonioacetaldehyde	0
ammonioacetone	0
ammonium +	50
anthranilate +	0
beta-D-fructofuranose 2,6-bisphosphate(4-)	0
beta-D-mannosyldiacetylchitobiosyldiphosphodolichol	0
biotin +	0
biotinate +	0
biotinyl-5'-AMP(1-)	0
but-1-ene-1,2,4-tricarboxylate	0
butane-2,3-dione	0
carbamoyl phosphate(2-)	0
carbon dioxide	7
carboxyacetyl-[acyl-carrier protein]	0
cerotate +	0
chitin	0
chitosan	0
cholesta-5,7-dien-3beta,25-diol	0
choline +	13
choline alfoscerate	0
choline phosphate(1-)	0
chorismate(2-) +	0
chorismic acid +	0
cis-aconitate(3-)	0
coenzyme A(4-) +	0
coproporphyrinogen III(4-)	0
cytidine +	0
cytidine 5'-monophosphate(2-) +	0
cytosine +	0
dADP(3-)	0
dATP(4-)	0
dCDP(3-) +	0
dCTP(3-)	0
dGDP(3-)	0
dGTP	0
dGTP(3-)	0
dITP(4-)	0
dTDP(3-)	0
dTTP(3-)	0
dUDP(3-)	0
dUMP(2-) +	0
dUTP(3-)	0
deamido-NAD(+) +	1
decanoate +	0
decanoyl-CoA(4-) +	0
decaprenyl diphosphate +	0
dehydro-D-arabinono-1,4-lactone(1-)	0
delta-tocotrienol	0
dethiobiotin(1-)	0
diglyceride +	0
dihydrofolate(2-)	0
dihydrolipoamide +	0
dihydrolipoylprotein	0
dihydromonacolin L acid +	0
dihydroxyacetone +	0
dihydroxyacetone phosphate	0
dioxygen +	12
diphosphate(3-) +	0
docosaprenyl diphosphate	0
dodecanoate +	0
dodecaprenyl diphosphate +	0
dolichol +	0
dolichyl D-mannosyl phosphate +	0
dolichyl phosphate +	0
episterol +	0
episteryl oleate	0
episteryl palmitoleate	0
ergosta-5,7,22,24(28)-tetraen-3beta-ol	0
ergosta-5,7,24(28)-trien-3beta-ol	0
ergosterol +	0
ergosteryl 3-beta-D-glucoside	0
ergosteryl oleate	0
ergosteryl palmitoleate	0
erythro-4-hydroxy-L-glutamic acid	0
ethanol +	99
ethanolaminium(1+) +	0
ethoxide +	0
ethyl (2R)-lactate +	0
ethyl (2S)-lactate +	0
ethyl acetate	0
fMet-tRNA(fMet)	0
fecosterol +	0
fecosteryl oleate	0
fecosteryl palmitoleate	0
ferricytochrome c +	0
ferrocytochrome c +	0
ferroheme b(2-)	0
folate(2-)	0
formaldehyde +	0
formate +	0
fumarate(2-) +	0
gamma-Glu-Ala	0
gamma-Glu-Ala(1-)	0
gamma-aminobutyric acid +	1
geranyl diphosphate(3-)	0
glutathionate(1-) +	0
glutathione disulfide(2-)	0
glyceraldehyde 3-phosphate(2-)	0
glycerol +	15
glycerone phosphate(2-)	0
glycogen	0
glyoxylate +	0
glyoxylic acid +	0
guanine +	9
guanosine 5'-monophosphate(2-) +	0
heme a +	0
heme o +	0
henicosaprenyl diphosphate	0
heptadecaprenyl diphosphate	0
heptaprenyl diphosphate +	0
hexacosanoyl-CoA +	0
hexadec-2-enoyl-CoA +	0
hexadecanal +	0
hexadecanoate +	0
hexadecaprenyl diphosphate	0
hexaprenyl diphosphate +	0
homocitrate(3-)	0
homocysteine zwitterion	0
homoisocitrate(3-) +	0
hydrogen peroxide +	48
hydrogencarbonate +	1
hydrogenphosphate +	0
hydrogensulfite +	0
hydrosulfide +	0
icosaprenyl diphosphate	0
indol-3-ylacetaldehyde	0
indole-3-acetate	0
inosine +	0
iron(2+) +	0
isoamyl acetate	0
isoamylol +	0
isobutanol +	0
isobutyl acetate	0
isobutyraldehyde +	0
isocitrate(3-) +	0
isopentenyl diphosphate(3-)	0
itaconate(2-)	0
itaconyl-CoA(5-)	0
keto-D-fructose 1,6-bisphosphate	0
keto-phenylpyruvate	0
kynurenic acid +	0
lanosterol +	0
lanosteryl oleate	0
lanosteryl palmitoleate	0
lauroyl-CoA(4-) +	0
leukotriene A4(1-)	0
leukotriene B4(1-)	0
lipoamide +	0
lipoylprotein	0
malonyl-CoA(5-)	0
maltose +	0
mannan +	0
mannitol +	0
mannose-(1D-myo-inositol 1-phosphate)2	0
mannose-1D-myo-inositol 1-phosphate	0
melibiose +	0
methanethiol +	0
methionine +	0
methylglyoxal +	1
myo-inositol +	0
myo-inositol 1,3,4,5,6-pentakisphosphate(10-)	0
myo-inositol hexakisphosphate(12-)	0
myristoyl-CoA(4-) +	0
nicotinamide +	3
nicotinate +	0
nicotinate D-ribonucleotide(2-)	0
nonadecaprenyl diphosphate	0
nonaprenyl 4-hydroxybenzoate	0
nonaprenyl diphosphate +	0
octadecanoate +	0
octadecaprenyl diphosphate	0
octanoate +	0
octanoyl-CoA(4-) +	0
octanoyl-[acyl-carrier protein]	0
octaprenyl diphosphate +	0
oleate +	0
oleoyl-CoA(4-)	0
ornithinium(1+) +	0
orotate +	0
orotidine 5'-phosphate(3-)	0
oxaloacetate(2-)	0
palmitoleate +	0
palmitoleoyl-CoA(4-) +	0
palmitoyl-CoA(4-)	0
pantetheine 4'-phosphate(2-) +	0
pectin +	0
pentadecaprenyl diphosphate	0
pentaprenyl diphosphate +	0
phenethyl acetate	0
phenylacetaldehyde +	0
phenylacetate +	0
phenylacetic acid +	0
phytosphingosine +	0
phytosphingosine 1-phosphate +	0
pimeloyl-CoA(5-)	0
polysulfur	0
porphobilinogen(1-)	0
potassium atom +	4
precorrin-2(7-)	0
prenyl diphosphate(3-)	0
preuroporphyrinogen(8-)	0
prop-2-yn-1-ol +	0
propionyl-CoA(4-) +	0
propyl decanoate	0
protoporphyrinate	0
protoporphyrinogen(2-)	0
pseudouridine 5'-phosphate(2-)	0
pyridoxal +	0
pyridoxal 5'-phosphate +	0
pyridoxal 5'-phosphate(2-)	0
pyridoxal hydrochloride	0
pyridoxamine +	0
pyridoxamine 5'-phosphate	0
pyridoxamine 5'-phosphate(1-)	0
pyridoxamine dihydrochloride	0
pyridoxamine hydrochloride	0
pyridoxaminium(1+) +	0
pyridoxine +	0
pyridoxine 5'-phosphate(2-)	0
quinaldic acid	0
quinolinate(2-)	0
raffinose +	0
riboflavin(1-) +	0
sedoheptulose 1,7-bisphosphate(4-)	0
sedoheptulose 7-phosphate(2-)	0
shikimate +	0
shikimic acid +	0
siroheme(8-)	0
sirohydrochlorin(8-)	0
sn-glycerol 3-phosphate(2-)	0
sodium atom +	60
sodium glyoxylate	0
sodium orotate	0
sphinganine 1-phosphate(1-)	0
sphinganine(1+) +	0
squalene +	0
stearoyl-CoA(4-)	0
succinate(2-) +	0
succinyl-CoA(5-)	0
sucrose +	0
sulfate +	1
tRNA(Ala) +	0
tRNA(Arg) +	0
tRNA(Asn) +	0
tRNA(Asp) +	0
tRNA(Cys) +	0
tRNA(Gln) +	0
tRNA(Glu) +	0
tRNA(Gly) +	0
tRNA(His) +	0
tRNA(Ile) +	0
tRNA(Leu) +	0
tRNA(Lys) +	0
tRNA(Met) +	0
tRNA(Phe) +	0
tRNA(Pro) +	0
tRNA(Ser) +	0
tRNA(Thr) +	0
tRNA(Trp) +	0
tRNA(Tyr) +	0
tRNA(Val) +	0
taurine +	22
taurocholate +	0
tetracosanoate +	0
tetracosanoyl-CoA	0
tetradecanoate +	0
tetradecaprenyl diphosphate +	0
tetrahydropteroyltri-L-glutamate(4-)	0
thiamine(1+) +	0
thiamine(1+) diphosphate(1-)	0
thiamine(1+) monophosphate +	0
thiamine(1+) triphosphate(4-)	0
thioredoxin disulfide	0
thioredoxin dithiol	0
trans-2-hexacosenoyl-CoA	0
trans-2-octadecenoyl-CoA	0
trans-dec-2-enoyl-CoA(4-)	0
trans-dodec-2-enoyl-CoA(4-)	0
trans-tetradec-2-enoyl-CoA(4-)	0
tridecaprenyl diphosphate +	0
trimethylenediaminium	0
tryptophol +	0
ubiquinol-6	0
ubiquinone-6	0
undecaprenyl diphosphate +	0
uracil +	1
urea +	6
urea-1-carboxylate	0
ureidoglycolic acid +	0
uridine 5'-monophosphate(2-) +	0
uroporphyrinogen III(8-)	0
water +	4
xylitol +	0
zymosterol +	0
zymosterol intermediate 1c	0
zymosterol intermediate 2	0
zymosteryl oleate	0
zymosteryl palmitoleate	0

paths to the root